



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email
info.bmjopen@bmj.com

BMJ Open

Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks in Spain: A protocol for an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051278
Article Type:	Protocol
Date Submitted by the Author:	16-Mar-2021
Complete List of Authors:	Gabaldon-Figueira, Juan; Clínica Universidad de Navarra, Área de Enfermedades Infecciosas Brew, Joe; Hyfe Inc Doré, Dominique; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Immunopathology Axis Umashankar, Nita; San Diego State University Chaccour, Juliane ; Clínica Universidad de Navarra, Área de Enfermedades Infecciosas Orrillo, Virginia; University of Navarra, School of Pharmacy and Nutrition Tsang, Lai Yu; Stony Brook University, Global Health Institute Blavia, Isabel; University of Navarra, School of Pharmacy and Nutrition Fernández-Montero , Alejandro ; Clínica Universidad de Navarra Bartolomé, Javier; Servicio Navarro de Salud - Osasunbidea Grandjean Lapierre, Simon; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Immunopathology Axis; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Department of Microbiology, Infectious Diseases and Immunology Chaccour, C; Universitat de Barcelona, ISGlobal; Clínica Universidad de Navarra, Area of Infectious Diseases
Keywords:	COVID-19, Respiratory infections < THORACIC MEDICINE, Epidemiology < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2 **Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks in Spain:**
3 **A protocol for an observational study**

4 Juan C. Gabaldón-Figueira^{a*} [jgabaldonfi@unav.es] (ORCID: 0000-0002-2525-0263)

5 Joe Brew^b [joe@hyfe.ai] (ORCID: 0000-0002-4119-0117)

6 Dominique Hélène Doré^c [dominique.helene.dore@umontreal.ca]

7 Nita Umashankar^d [numashankar@sdsu.edu]

8 Juliane Chaccour^a [jchaccour@gmail.com] (ORCID: 0000-0001-5611-9690)

9 Virginia Orrillo^e [vorrillo@alumni.unav.es]

10 Lai Yu Tsang^f [Lai.Tsang@stonybrookmedicine.edu]

11 Isabel Blavia^e [iblavia@alumni.unav.es]

12 Alejandro Fernandez-Montero^a [afmontero@unav.es]

13 Javier Bartolomé^g [fjbr@medena.es]

14 Simon Grandjean Lapierre^{c,i} †

15 [simon.grandjean.lapierre@umontreal.ca] (ORCID 0000-0003-3646-1573)

16 Carlos Chaccour^{h, a, j} † [carlos.chaccour@isglobal.org] (ORCID 0000-0001-9812-050X)

17

18 *Corresponding author

19 †These authors contributed equally

20 **Corresponding author's contact information**

21 Juan C. Gabaldón-Figueira

22 E: jgabaldonfi@unav.es

23 Address: Av. Pío XII, 36, Pamplona, Navarra, Spain. 31008.

24

25 **Affiliations**

26 ^a Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain

1
2
3 **27** ^b Hyfe Inc, Wilmington, DE, USA
4
5 **28** ^c Immunopathology Axis, Centre de Recherche du Centre Hospitalier de l'Université de
6
7 **29** Montréal, Montréal, Québec, Canada
8
9
10 **30** ^d San Diego State University, San Diego, CA, USA
11
12 **31** ^e School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
13
14 **32** ^f Stony Brook University, Global Health Institute, Stony Brook, New York, USA
15
16 **33** ^g Servicio Navarro de Salud- Osasunbidea, Zizur Mayor, Spain
17
18 **34** ^h ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
19
20 **35** ⁱ Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal,
21
22
23 **36** Montréal, Québec, Canada
24
25
26 **37** ^jIfakara Health Institute, United Republic of Tanzania.
27
28
29
30 **38**
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **40 Abstract**

3 **41 Introduction**

4 Cough is a landmark symptom of COVID-19 and other respiratory illnesses. However,
5 objectively measuring its frequency and evolution is hindered by the lack of reliable and
6 scalable monitoring systems. This can be overcome by newly developed artificial intelligence
7 models that exploit the portability of smartphones. In the context of the ongoing COVID-19
8 pandemic, cough detection for respiratory disease syndromic surveillance represents a simple
9 means for early outbreak detection and disease surveillance. In this protocol, we evaluate the
10 ability of population-based digital cough surveillance to predict the incidence of respiratory
11 diseases at population level in Navarra, Spain, while assessing individual determinants of
12 uptake of these platforms.

13 **51 Methods and analysis**

14 Participants in the Cendea de Cizur, Zizur Mayor, or attending the local University of Navarra
15 (Pamplona) will be invited to monitor their night-time cough using the smartphone app Hyfe
16 Cough Tracker™. Detected coughs will be aggregated in time and space. Incidence of
17 COVID-19, and other diagnosed respiratory diseases within the participants cohort, and the
18 study area and population will be collected from local health facilities and used to carry out
19 an ARIMA analysis on those independent time series. In a mixed-methods design, we will
20 explore barriers and facilitators of continuous digital cough monitoring by evaluating
21 participation patterns, socio demographic characteristics. Participants will fill an
22 acceptability questionnaire and a subgroup will participate in focus group discussions.

23 **61 Ethics and dissemination**

24 Ethics approval was obtained from the ethics committee of the Centre Hospitalier de
25 l'Université de Montréal, Canada and the Medical Research Ethics Committee of Navarre,
26 Spain. Preliminary findings will be shared with civil and health authorities and reported to

1
2
3 65 individual participants. Results will be submitted for publication in peer-reviewed scientific
4
5 66 journals and international conferences.
6
7
8 67 **Trial Registration Number**
9
10 68 clinicaltrials.gov/NCT04762693

12 69
13
14 70
15
16 71
17
18 72
19
20 73
21
22 74
23
24 75
25
26
27
28 76
29
30 77
31
32 78
33
34 79
35
36
37 80
38
39 81
40
41 82
42
43 83
44
45
46 84
47
48 85
49
50 86
51
52 87
53
54 88
55
56 89
57
58 90
59
60

For peer review only

1
2
3 **91 Strengths and limitations of this study**

4
5 92 1. This is the first study to evaluate the utility of artificial intelligence models and
6 93 smartphone applications for cough detection at population level.

7
8
9 94 2. The studied approach has the potential to be rapidly scalable even within
10 95 underdeveloped public health systems.

11
12
13 96 3. Qualitative methods will improve the understanding of barriers and facilitators
14 97 affecting the uptake of cough detection smartphone applications and participation in acoustic
15 98 surveillance programs.

16
17
18 99 4. Recorded coughs will be annotated with clinical diagnoses (when available) and will
19 100 contribute to the training of cough-based disease-specific screening and diagnostic tools.

20
21 101 5. Success of this study is contingent on large-scale enrolment and high participant
22 102 retention since a small sample size might not be sufficient to appropriately correlate the study
23 103 population's cough trends and their relationship with the incidence of respiratory diseases at
24
25 104 population level.

1
2
3 105 **Introduction**
4
5

6 106 Real-time tracking of the COVID-19 pandemic and detection of the emergence of novel
7 107 variants or other respiratory pathogens represent challenges for public health authorities
8
9

10 108 globally. Nonetheless, understanding local epidemiology is essential to disease control efforts.
11
12

13 109 This is particularly true now that the world has moved into a COVID-19 endemic phase, with
14 110 periodic outbreaks in multiple locations superimposed over ongoing community transmission.
15
16

17 111 The ability to appropriately monitor disease incidence, however, is frequently limited by a lack
18 112 of testing capacity, delays in health-seeking behaviours, as well as complexities related to
19 113 timely aggregation of actionable surveillance data by public health authorities.
20
21

22 114 Although asymptomatic cases of COVID-19 and other respiratory communicable diseases are
23 115 well described, cough remains a hallmark symptom of COVID-19 with as much as 75% of
24 116 infected patients reporting cough as an early symptom. (1, 2) Additionally, coughing increases
25
26

27 117 person to person transmission. Automatically detecting cough sounds is now possible thanks
28 118 to the recent development of acoustics and artificial intelligence (AI) models which can be
29 119 deployed on smartphone applications.(3) In brief, putative cough sounds (manifested as short
30 120 and explosive noises) are recognized and captured by smartphones. Machine learning models
31
32

33 121 trained on hundreds of thousands of annotated sounds are then used to distinguish cough
34 122 from other sounds. Similar approaches were also taken one step further and shown to have
35
36

37 123 value in COVID-19 specific cough recognition for disease screening and diagnosis. (4, 5)

38
39 124 We propose that COVID-19 surveillance and early outbreak recognition can be enhanced by
40 125 digitally monitoring cough and detecting changes in its incidence at population level. We
41
42

43 126 hypothesize such changes precede individual symptoms recognition, healthcare seeking
44 127 behaviours, diagnosis and data aggregation within conventional disease surveillance systems.
45
46

47 128 Indeed, digital cough monitoring data can be aggregated in real time providing constantly
48 129 updated information on the emergence and activity of communicable respiratory diseases
49 130 within populations. This approach would be of particular value in low- and middle-income
50
51

1
2
3 131 countries where (a) capturing passive data through health services is insufficient given
4 132 unequal access to healthcare, and (b) active case detection and contact tracing capacity is
5 133 limited. (6, 7)
6
7
8 134 To our knowledge, digital cough monitoring for early detection of respiratory disease
9 135 outbreaks has never been performed. Provided the participation of a critical mass of active
10 136 users is achieved, monitoring of aggregated cough data could provide a simple and
11 137 inexpensive surrogate indicator for overall respiratory infections incidence, similar to, but
12 138 more accurate than wastewater monitoring (8). This information could in turn guide public
13 139 health interventions. If proven successful in the specific case of COVID-19, this study would
14 140 establish a template for early and disease-agnostic detection of emerging pathogens,
15 141 therefore contributing to health systems epidemic preparedness.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30 142
31
32 143 **Primary research question**
33
34 144 Can digital cough surveillance predict the incidence of respiratory diseases at population-level
35 145 in Navarra, Spain?
36
37 146
38
39 147 **Methods**
40
41 148 **Study design**
42
43 149 This is a prospective observational study which will take place between November 2020 and
44
45 150 October 2021 (Figure 1). Participants will be recruited in (a) the Cendea de Cizur, a
46
47 151 municipality composed by a cluster of villages south of the city of Pamplona, (b) the
48
49 152 neighbouring town of Zizur Mayor, in the Chartered Community of Navarra (Spain), as well as
50
51 153 (c) in the different campuses of the University of Navarra (Pamplona), which collides with the
52
53 154 municipalities.
54
55
56
57
58
59
60

1
2
3 155 All these communities are located within a 5 km range from each other, and there is a
4
5 156 considerable geographical and social overlap between them, as the University of Navarra is
6
7 157 the second most important employer in the area.
8
9
10 158 The 4,000 people living in the Cendea de Cizur are served by a public health center which
11
12 159 receives 45,000 outpatients visits per year. Of these, approximately 12% are associated with
13
14 160 respiratory diseases. Furthermore, the Clínica Universidad de Navarra is the main private
15
16 161 healthcare provider in the region and offers medical care to a significant proportion of the
17
18 162 population, as well as university students and workers. Both centres offer COVID-19 PCR
19
20 163 testing. Together, those two healthcare facilities cover most of the population's healthcare
21
22 164 needs and have digitalized medical record systems that facilitate the retrieval of medical data
23
24 165 concerning the diagnosis of respiratory diseases among participants.

25
26
27 166 Recruitment strategies will include direct solicitation, community meetings, videos and
28
29 167 advertisements in social media and university communication platforms. Those willing to
30
31 168 participate will attend individual sessions with a study coordinator for counselling and training
32
33 169 using the Hyfe Cough Tracker™ (Hyfe™) application, and for obtention of informed consent
34
35 170 (Supplementary material). Participants will consent to be contacted regularly via email and
36
37 171 telephone by the study team and will also fill an enrolment questionnaire (Supplementary
38
39 172 material) where demographic and respiratory diseases medical data will be collected.

40
41
42 173

43
44
45 174 **Primary objective**

46
47 175 1. To assess the value of digital cough monitoring and acoustic surveillance in predicting
48
49 176 COVID-19 and other respiratory diseases incidence at population level.

50
51
52 177 **Secondary objective**

53
54 178 2. To assess barriers and facilitators to participation in an acoustic surveillance program
55
56 179 using a smartphone-based digital cough monitoring application.

57
58
59 180

1
2
3 **181 Eligibility criteria**

4
5 182 To be included in the study, participants must (i) be 13 years old or older, (ii) own a
6 183 smartphone, (iii) be willing to install and use the Hyfe™ digital cough monitoring application,
7
8 184 (iv) accept and comply with Hyfe™ privacy policy and terms of use, and (v) grant access to
9 185 their medical records. To optimize population representativity, participants also need to (vi)
10 186 visit the University of Navarra on a regular basis, either as a student, worker, or patient of the
11 187 university clinic, or (vii) have a general interest in the study, and (viii) currently reside in
12
13 188 Navarra. These criteria aim at ensuring a large sample size and the availability of needed
14
15 189 medical records while concentrating recruitment in a geographically focused area.

16
17
18 **190**
19 **191 Participant retention**

20
21 192 To ensure participants' retention and promote continuous cough recording, we will use videos
22
23 193 posted on social media, as well as emailed to participants, text messages and regular push
24
25 194 notifications sent via the Hyfe™ application on participants' smartphones. Participants will
26
27 195 also receive monthly emails with information regarding the current stage of the study and
28
29 196 high-level preliminary results.

30
31
32 **197**
33 **198 Digital cough monitoring**

34
35 199 The cough detection application used in this study is Hyfe Cough Tracker™ (Hyfe™).
36
37 200 (<https://www.hyfeapp.com/>). Hyfe™ runs in the background of smartphones operating
38
39 201 systems, listens for and records short snippets (<0.5 seconds) of explosive, putative cough
40
41 202 sounds and then classifies them as cough or non-cough, using a convolutional neural network
42
43 203 model. Cough sounds are automatically matched with time and GPS coordinates which can be
44
45 204 jittered to ensure participants' privacy. Hyfe™ is a research tool that has collected over 5
46
47 205 million putative cough sounds, of which over 1,000,000 have been classified as coughs or not
48
49 206 by a human listener in order to train the AI model.

1
2
3 207 The analytical performance of Hyfe™ for cough detection was confirmed using this study's
4
5 208 preliminary results from a subgroup of participants recruited in the Cendea de Cizur between
6
7 209 November and December 2020. Analytical performance refers to whether the application is
8
9 210 sensitive and specific for the classification of recorded sounds as coughs or non-coughs.
10
11 211 During this period, nearly 700,000 putative cough sounds were registered, of which 119,876
12
13 212 were classified by human observers, revealing a sensitivity of 96.34% and a specificity of
14
15 213 96.54%, when using a cough-positivity threshold of 0.85 (Figure 2).
16
17
18
19
20 214
21
22 215 Upon enrolment, a study coordinator will assist participants in installing the Hyfe™
23
24 216 application. Once turned on, it will continuously monitor participants' cough. Participants can
25
26 217 turn the application on and off at will but will be instructed to keep it active for at least six
27
28 218 hours or while they sleep, every day for a minimum period of 30 days. In an adaptive design
29
30 219 aimed at improving retention, participants will have the possibility of extending their
31
32 220 participation to a 3-month and 6-month period.
33
34
35
36 221
37
38 222 **Local epidemiology of respiratory disease**
39
40 223 Digital medical data systems at the Zizur's health center and the Clínica Universidad de
41
42 224 Navarra will be reviewed monthly to establish the incidence of the following respiratory, or
43
44 225 cough-associated diseases in the participants cohort; COVID-19, influenza, respiratory
45
46 226 syncytial virus (RSV), pneumonia, asthma, bronchitis, pharyngitis, chronic cough, chronic
47
48 227 obstructive pulmonary disease (COPD), gastro-esophageal reflux disease (GERD), other
49
50 228 nonspecific respiratory tract infections. Specifically, for COVID-19, daily incidence figures for
51
52 229 the study area (Cendea de Cizur, Zizur Mayor, and Pamplona), and regional population, will
53
54 230 also be obtained from local health authorities. Data will be aggregated and used to build local
55
56 231 epidemic curves of respiratory diseases during the study period.
57
58
59
60 232

1
2
3 **233 Barriers and facilitators to participation**

4
5 234 A participation cascade informing on the number of solicited, enrolled, and actively recording
6 participants will be tracked in real time throughout the study. The total number of user-hours
7
8 235 using Hyfe™ will also be monitored in real time.
9
10

11 237 All participants will be asked to fill a satisfaction survey in which they will be asked about the
12 usability of the app, the problems that they ran into, and their likelihood of using the app in
13
14 238 the future. We will follow-up with a group of 25 participants who are willing to attend a focus
15 239 group discussion (FGD) to better understand the barriers and facilitators affecting
16 240 participation in the cough-surveillance system. The 25 participants will include some of whom
17
18 241 deleted the application early on, who stopped using it after a month, and who had low
19
20 242 satisfaction scores.
21
22
23
24
25
26
27
28
29

30 **244 Patient and public involvement**

31
32 245 This study pilots an experimental syndromic surveillance approach at population level. The
33
34 246 municipal authorities of the Cendea de Cizur were informed about the nature of the study and
35
36 247 provided feedback on the best approach to recruit local participants. Similarly,
37
38 248 representatives of the University of Navarra's medical services collaborated on the design of
39
40 249 the study protocol including the review of recruitment strategies as well as data collection,
41
42 250 aggregation and reporting plans. No anticipated participants were involved in the study
43
44 251 design. Study findings are to be reported in both English and Spanish to participants and key
45
46 252 stakeholders at individual, municipality, and university levels during the surveillance phase.
47
48
49
50
51

52 **254 Data analysis and sample size calculations**

53
54 **255 Syndromic surveillance as a surrogate marker of respiratory disease activity**

55
56 256 Given the uncertainty around the incidence of the various respiratory diseases including
57
58 257 COVID-19, throughout the study period, it is impossible to establish a target sample size
59
60

1
2
3 259 sufficient to either confirm or confute with statistical significance that cough monitoring at
4
5 260 population level can predict incidence of respiratory diseases. We will endeavour to recruit
6
7 261 the highest number of participants possible in order to achieve the best representation of the
8
9 262 population.

10
11 263 First, cough data will be aggregated in time and space to create cough incidence curves and
12
13 264 geospatial heat maps reflecting the frequency and density of cough among the studied
14
15 265 population (Figure 3 and Figure 4). Second, epidemic curves reflecting the incidence of
16
17 266 targeted respiratory illnesses within the participants cohort, and the number of COVID-19
18
19 267 cases diagnosed in the study area and population will be generated with data collected from
20
21 268 the Clínica Universidad de Navarra, and Zizur's health center, as well as aggregated
22
23 269 epidemiological records obtained from regional health authorities, respectively. Coughs per
24
25 270 person-hour and clinical diagnoses data will be superposed in time. Finally, we will carry out
26
27 271 an autoregressive moving average (ARIMA) analysis to compare the incidence of confirmed
28
29 272 and forecasted respiratory diseases (including COVID-19) with the frequency of cough among
30
31 273 study participants, measured as coughs per person-hour. ARIMA analysis is a type of time
32
33 274 series analysis that uses past data to forecast the likely future behaviour of a variable. In brief,
34
35 275 the variable of interest is regressed to its own lagged values, and autoregression and partial
36
37 276 autocorrelation functions are used to model the stochastic nature of a time series. (9)
38
39 277 Comparison and prediction analyses will be performed using epidemic curves from both the
40
41 278 participants cohort and in the entire study area and population.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

279 280 **Perceptions and willingness to participate in syndromic surveillance**

281 Mixed methods will be used to assess individual barriers and facilitators to participation in an
282 acoustic surveillance program. Among all eligible individuals in the Cendea de Cizur, Zizur
283 Mayor and in the University of Navarra who are invited to participate in the study, we will
284 assess how many do install the cough detection application and keep using it through the

1
2
3 285 course of the study. Participants corresponding to specific user profiles based on duration and
4 regularity of cough recording will be identified. We will then descriptively analyze the socio-
5 demographic characteristics, and baseline health conditions of participants belonging to the
6 different user profiles.
7
8
9
10
11
12

13 289 A subsample of participants will be contacted once a month, by telephone or text messaging,
14 290 to obtain feedback from their experience using the app.
15
16

17 291 To assess population uptake of Hyfe™, as well as barriers and facilitators to participation, a
18 292 convenience subsample of 25 participants will be recruited for focus group discussions.
19
20
21

22 293 Following similar designs, FGDs will consist of two parts. (10) The first one will be aimed at
23 294 understanding a participant's awareness of their cough frequency and temporality patterns,
24 295 as well as the perceived importance of measuring these elements. Questions asked in this part
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

296 will include (i) How much attention do you pay to your coughs on a daily basis? (ii) How
297 important is it for you to know the number of times you cough per day? (iii) Will keeping track
298 of your coughs help you improve your health? The second one will focus on the participant's
299 experience using Hyfe™, as well as possible recommendations for developers to improve it.
300 This part will include the following general questions: (i) What do you like about the app, (ii)
301 What do you think of this app compared to other health apps, (iii) What doesn't work well,
302 (iv) What keeps you committed (or not) to using the app, (v) What do you think the purpose
303 of the app is, (vi) What advice do you have for the developers?
304
305 **Risks and privacy**
306 Recording sounds implies specific ethical and privacy concerns. These are, however,
307 addressable at different levels. First, sound snippets recorded are too short (<0.5 seconds) to
308 capture conversations or background sound. Participants can withdraw from the study at any
309 time, and the application can be turned off or removed from smartphones freely. Our consent

1
2
3 310 process explicitly describes exactly what is and what is not recorded. The use of pre-generated
4
5 311 unique identifiers to install and use the smartphone application ensures that only
6
7 312 investigators can link cough data to personal identifiers. Contact information collected from
8
9 313 participants will be kept in physical forms stored under lock, and password-protected files at
10
11 314 the University of Navarra. Only the principal investigator, study coordinator, and research
12
13 315 assistant will have access to this information.
14
15
16 316
17
18 317 **Ethics and dissemination**
19
20 318 This study protocol was approved by the ethics committee of the Centre Hospitalier de
21
22 319 l'Université de Montréal, Canada (Reference numbers 2021-9247 20.253 & 2021-9270 20.226)
23
24 320 and the Medical Research Ethics Committee of Navarra, Spain (Reference number
25
26 321 PI107/2020). Any modifications to the approved protocol would be resubmitted to both
27
28 322 committees.
29
30
31 323 Preliminary summary results of this study will be regularly shared with participants via email
32
33 324 and through focal meetings. Final results will also be disseminated in open-access scientific
34
35 325 journals and international conferences. A two-page summary of results will be prepared in
36
37 326 Spanish and posted on the municipal and university website, and shared with local civil and
38
39 327 health authorities, as well as with individual participants.
40
41
42 328
43
44
45 329 **Discussion**
46
47 330 The current COVID-19 pandemic highlights the incapacity of existing surveillance networks to
48
49 331 rapidly curb the impact of emerging respiratory pathogens in the current globalized world.
50
51 332 (11) This is particularly true in low- and middle-income countries, where diagnostic and
52
53 333 contact-tracing efforts are limited by their crippling costs, and where epidemiological data
54
55 334 aggregation infrequently translates into actionable information because of delays inherent to
56
57 335 disaggregated and poorly digitalized health information systems. Continuous, individual-

1
2
3 336 based, and passive monitoring of cough among entire populations could represent
4 337 inexpensive large-scale surveillance networks contributing to the early detection of outbreaks
5 338 and enabling prioritized and focal delivery of limited resources.
6
7
8
9
10

11 339
12 340 AI and more specifically machine learning models, are increasingly used in disease surveillance
13 341 and can maximize the impact of limited available resources. (12) Integration of such models
14 342 with accurate digital epidemiological data was shown to provide reliable, near-real time
15 343 estimations of influenza disease incidence. (13) The widespread distribution of smartphones
16 344 coupled with the development of AI-enabled sound classification models now represent
17 345 another new potential breakthrough in public health and epidemic preparedness. Beyond
18 346 being able to detect cough, most smartphones have integrated geo-location functions. This
19 347 allows the integration of acoustic records with geo-spatial and temporal data and increases
20 348 the range of applications of acoustic surveillance systems for disease control. (14)
21
22

23 349
24
25 350 Apart from participating in a collective disease tracking and eradication effort, participants
26 351 monitoring their cough also benefit from objective feedback on their own symptomatology.
27
28 352 During a pandemic, such feedback could trigger appropriate healthcare seeking behaviours
29 353 and self-quarantine further helping to limit disease transmission at community level.
30
31

32 354
33
34 355 Implementing such an innovative approach to disease surveillance is contingent on
35 356 overcoming substantial challenges. Evidence suggests that users are typically willing to install
36 357 mobile apps with a clearly perceived health benefit. But this is often limited by issues such as
37 358 increased battery drainage, or disruption of daily activities by alerts and notifications. (15)
38
39 359 Specifically, for acoustic surveillance apps, protecting user's privacy must also be a priority, in
40 360 order to create the social trust needed to achieve a high uptake of these systems. To
41 361 guarantee this, users must be able to clearly understand the nature of these applications, as
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 362 well as to control their functioning at will. This means that the quality of the data recorded
4
5 363 will greatly depend on individual behaviours.
6
7 364
8
9
10 365 Despite proven technical capacity and tremendous potential in complementing surveillance
11
12 366 systems, whether listed challenges can be overcome and whether digital cough monitoring
13
14 367 can provide actionable public health information remains unknown. This study will address
15
16 368 those questions. It will also generate operational expertise and qualitative knowledge on the
17
18 369 facilitators to be exploited, and the barriers to be addressed in order to maximize uptake and
19
20 370 impact prior to implementation on a wider scale.

21 371
22
23
24
25
26 372 **Limitations and potential challenges**
27
28
29
30 373 Enrolment and retention are expected to represent the major limitations of this project.
31
32 374 Acoustic syndromic surveillance tools might be perceived as threatening for the privacy of
33
34 375 potential participants. Furthermore, the quantity of cough data recorded will heavily rely on
35
36 376 the regular use of the system by participants. The diversity of respiratory and non-respiratory
37
38 377 conditions that can cause cough, as well as the consumption of medications to treat them,
39
40 378 can make it difficult to link changes in cough frequency with epidemiological data. Finally,
41
42 379 asymptomatic, or mild infections of SARS-CoV-2 and other respiratory pathogens, mean that
43
44 380 a proportion of infected patients will not contribute to the cough-based surveillance system
45
46 381 and are unlikely to seek medical attention, reducing available cough and epidemiological data
47
48 382 necessary for the analysis. Those limitations and challenges reflect well the impediments to
49
50 383 larger scale deployment of cough-based syndromic surveillance for any respiratory disease
51
52 384 hence making this innovative study an ideal stress-test for such approach.

1
2 **385 Acknowledgements**

3
4 386 The authors want to thank the Municipality of the Cendea de Cizur, the University of Navarra
5
6 387 and all participants for their trust and desire to participate in citizen science and altruistic
7
8 388 population-level syndromic surveillance.

9
10 389
11
12 **390 Contributors**

13
14 391 All authors meet criteria for authorship as per the BMJ Global Health policy and ICJME
15
16 392 recommendations. Conceptualization (JCGF, JB, DD, NU, LYT, SGL, CCh), data curation (JCGF,
17
18 393 JB, NU, CCh), formal analysis (JCGF, JB, NU, SGL, CCh), funding acquisition (SGL),
19
20 394 investigation (JCGF, JCh, ALP, VO, IB, JBart, CCh), methodology (JCGF, JB, NU, SGL, CCh),
21
22 395 supervision (JCGF, SGL, CCh), writing of the original draft (JCGF, CCh, SGL). All authors have
23
24 396 read, reviewed, discussed, and approved the final manuscript and their respective
25
26 397 representation in the authorship.

27
28 **398 Data sharing statement**

29
30 399 Aggregated deidentified datasets will be available upon completion of the study by
31
32 400 reasonable request to the corresponding author.

33
34 **401 Funding**

35
36 402 This study was funded by the *Patrick J. McGovern Foundation* (grant name: "Early diagnosis of
37
38 403 COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring"). The funders had no role
39
40 404 in study design, data collection and interpretation, or the decision to submit the work for
41
42 405 publication. CCh received salary support from Unitaid (grant name: BOHEMIA). ISGlobal
43
44 406 acknowledges support from the Spanish Ministry of Science and Innovation through the
45
46 407 "Centro de Excelencia Severo Ochoa 2019-2023" Program (grant number: CEX2018-000806-
47
48 408 S), and support from the Generalitat de Catalunya through the CERCA program.
49
50 409

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

410 Competing interest

411 JB is the CEO of Hyfe™ Inc. Hyfe Inc had no role in the decision to submit this protocol for
412 publication. All other authors declare no competing interests. Upon submission of this
413 protocol for publication, JCG, SGL and CCh had full access to all the data available and assumed
414 responsibility for the decision to submit the manuscript content for publication.

415

416 References

417 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
418 with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.

419 2. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of
420 asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect*.
421 2020;26(7):948.e1-e3. PubMed PMID: 32360780. Epub 05/01. eng.

422 3. Rasheed J, Jamil A, Hameed AA, Aftab U, Aftab J, Shah SA, et al. A survey on artificial
423 intelligence approaches in supporting frontline workers and decision makers for the COVID-
424 19 pandemic. *Chaos, Solitons, and Fractals*. 2020;141:110337 -

425 4. Mouawad P, Dubnov T, Dubnov S. Robust Detection of COVID-19 in Cough Sounds. *SN*
426 Computer Science. 2021 2021/01/12;2(1):34.

427 5. Laguarta J, Suerto F, Subirana B. COVID-19 Artificial Intelligence Diagnosis Using Only
428 Cough Recordings. *Open Journal of Engineering in Medicine and Biology*. 2020;1:275-81.

429 6. Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al.
430 Serology testing in the COVID-19 pandemic response. *The Lancet Infectious Diseases*. 2020
431 2020/09/01;/20(9):e245-e9.

432 7. Chowdhury R, Luhar S, Khan N, Choudhury SR, Matin I, Franco OH. Long-term
433 strategies to control COVID-19 in low and middle-income countries: an options overview of
434 community-based, non-pharmacological interventions. *European Journal of Epidemiology*.
435 2020 2020/08/01;35(8):743-8.

436 8. Farkas K, Hillary LS, Malham SK, McDonald JE, Jones DL. Wastewater and public
437 health: the potential of wastewater surveillance for monitoring COVID-19. *Curr Opin Environ*
438 *Sci Health*. 2020;17:14-20. PubMed PMID: 32835157. Epub 06/12. eng.

439 9. Ho SL, Xie M. The use of ARIMA models for reliability forecasting and analysis.
440 *Computers & Industrial Engineering*. 1998 1998/10/01/;35(1):213-6.

441 10. Nouvet E, Knoblauch AM, Passe I, Andriamiadanarivo A, Ravelona M, Ainanomena
442 Ramtariharisoa F, et al. Perceptions of drones, digital adherence monitoring technologies and
443 educational videos for tuberculosis control in remote Madagascar: a mixed-method study
444 protocol. *BMJ Open*. 2019;9(5):e028073.

- 1
2
3 445 11. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; 2021 [cited
4 446 2021 06/03]. Available from: <https://covid19.who.int/>.
- 5
6 447 12. Naseem M, Akhund R, Arshad H, Ibrahim MT. Exploring the Potential of Artificial
7 Intelligence and Machine Learning to Combat COVID-19 and Existing Opportunities for LMIC:
8 A Scoping Review. Journal of Primary Care & Community Health. 2020
9 450 2020/01/01;11:2150132720963634.
- 10
11 451 13. Santillana M, Nguyen AT, Louie T, Zink A, Gray J, Sung I, et al. Cloud-based Electronic
12 Health Records for Real-time, Region-specific Influenza Surveillance. Scientific Reports. 2016
13 453 2016/05/11;6(1):25732.
- 14
15 454 14. Mukundarajan H, Hol FJH, Castillo EA, Newby C, Prakash M. Using mobile phones as
16 acoustic sensors for high-throughput mosquito surveillance. eLife. 2017
17 455 2017/10/31;6:e27854.
- 18
19 457 15. Liss DT, Serrano E, Wakeman J, Nowicki C, Buchanan DR, Cesan A, et al. "The Doctor
20 Needs to Know": Acceptability of Smartphone Location Tracking for Care Coordination. JMIR
21 mHealth and uHealth. 2018 May 4;6(5):e112. PubMed PMID: 29728349. Pubmed Central
22 PMCID: PMC5960037. Epub 2018/05/08. eng.
- 23
24
25
26 461
- 27
28 462 **Supplementary materials**
- 29
30 463 1. Informed Consent Form
- 31
32 464 2. Assent form
- 33
34 465 3. Complementary medical questionnaire for participants
- 35
36 466 4. SPIRIT Checklist
- 37
38
39
40 467 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
41 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
42 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
43 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
44 Federal Government officers or employees acting as part of their official duties; on a
45 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its
46 licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the
47 Journal, to publish the Work in BMJ Global Health and any other BMJ products and to exploit
48 all rights, as set out in our [licence](#).
- 49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **476**
4
5 **477** The Submitting Author accepts and understands that any supply made under these terms is
6
7 **478** made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
8
9 **479** your employer or a postgraduate student of an affiliated institution which is paying any
10
11 **480** applicable article publishing charge ("APC") for Open Access articles. Where the Submitting
12
13 **481** Author wishes to make the Work available on an Open Access basis (and intends to pay the
14
15 **482** relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
16
17 **483** Commons licence – details of these licences and which [Creative Commons](#) licence will apply
18
19 **484** to this Work are set out in our licence referred to above.
20
21
22
23
24 **485** **Figure legends**
25
26
27 **486** **Figure 1:** Study design, timeline and monitoring plan for the study's primary objective.
28
29
30 **487** **Figure 2:** Receiver operating characteristic (ROC) analysis showing an area under the curve
31 **488** (AUC) of 0.995 for the classification of cough in participants recruited between November
32 **489** and December 2020.
33
34 **490** **Figure 3:** Coughs per person-hour registered in 62 participants between November 2020 and
35 **491** January 2021.
36
37 **492** **Figure 4:** Heatmap of registered cough episodes in the municipalities of Zizur Mayor, Cendea
38 **493** de Cizur, and Pamplona between November 2020 and March 2021 (The Cendea de Cizur is
39 **494** an incontiguous municipality).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

230x128mm (96 x 96 DPI)




Figure 2

147x79mm (96 x 96 DPI)





Figure 3

115x99mm (96 x 96 DPI)



157x151mm (96 x 96 DPI)



HOJA DE INFORMACIÓN Y CONSENTIMIENTO

Versión 3.0, 6 de enero de 2021

TÍTULO DEL ESTUDIO: Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.

CÓDIGO DEL PROMOTOR:

PROMOTOR

Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona.

FINANCIACIÓN:

Este estudio está siendo financiado por el Centre Hospitalier de l'Université de Montréal (CHUM) y la fundación Patrick J. McGovern a través de una subvención otorgada al co-investigador Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*).

INVESTIGADOR PRINCIPAL

Carlos Chaccour

Teléfono +34 666 293 112

Email cchaccour@unav.es

INTRODUCCIÓN

Nos dirigimos a usted para informarle sobre un estudio de investigación en el que se le invita a participar. El estudio ha sido aprobado por un Comité de Ética de la Investigación de la Universidad de Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité de ética del Centre Hospitalier de l'Universite de Montréal (CHUM), en Canadá.

Con este documento pretendemos que usted reciba la información adecuada para que pueda entender de qué se trata el estudio y decidir si desea o no participar en el mismo. Para ello, lea esta hoja informativa con atención y nosotros le aclararemos las dudas que puedan surgir después de la explicación. Además, puede consultar con las personas que considere oportuno.

PARTICIPACIÓN VOLUNTARIA



Debe saber que su participación en este estudio es voluntaria y que puede decidir no participar o cambiar su decisión y retirar el consentimiento en cualquier momento, sin que por ello se altere la relación con su médico ni se produzca perjuicio alguno en su tratamiento.

DESCRIPCIÓN GENERAL DEL ESTUDIO

Los coronavirus son un grupo de virus que causan infecciones respiratorias generalmente leves. Sin embargo, un miembro de este grupo, el SARS-CoV-2, es el responsable de provocar la COVID-19, una enfermedad potencialmente peligrosa que desde finales del 2019 se ha extendido a lo largo de todo el mundo.

Uno de los elementos necesarios para contener el avance de la pandemia de COVID-19 es entender su escala real. Esto es particularmente importante ahora que los brotes regulares en zonas en las que simultáneamente ocurre transmisión a una menor escala se han convertido en una realidad. Uno de los mayores obstáculos de los sistemas sanitarios es la limitada capacidad de hacer pruebas diagnósticas, lo que se traduce en retrasos en la búsqueda de atención médica, así como en la recolección de la información necesaria para planear intervenciones que limiten la expansión de la enfermedad.

La gran mayoría de pacientes con COVID-19 presentan tos como un síntoma temprano de la enfermedad. Este estudio pretende evaluar la utilidad de una aplicación para el móvil, llamada HyfeApp, que registra y evalúa patrones de tos, como complemento a las estrategias de vigilancia epidemiológica existentes. Para esto, estimamos que será necesario grabar y analizar episodios individuales de tos.

Por eso esperamos que el mayor número posible de habitantes instale la aplicación. Esta aplicación se ejecuta en segundo plano en el móvil. Aunque HyfeApp tiene acceso continuo al micrófono de su móvil, ha sido diseñada para procesar únicamente sonidos compatibles con las características de la tos humana. Cuando uno de estos sonidos es detectado y grabado por la aplicación, un algoritmo de inteligencia artificial lo estudia y en caso de decidir qué se trata de un episodio de tos, se guarda junto a la información sobre la ubicación geográfica y el momento en que ocurrió, que es proporcionada por el sistema GPS del móvil.

Aparte de la información suministrada por la aplicación, también revisaremos los registros médicos de aquellas personas dispuestas a participar que acudan a consulta en el sistema nacional de salud, o la Clínica Universidad de Navarra. El objetivo de esto es recolectar información sobre la presencia de tos durante la exploración médica, o el diagnóstico de alguna enfermedad respiratoria en alguna de las visitas. Solo se consultará información relacionada con alguna de las siguientes condiciones:

- TOS NO ESPECÍFICA.
- INFECCIONES DEL TRACTO RESPIRATORIO SUPERIOR.
- FARINGITIS.
- ASMA.
- BRONQUITIS.
- ENFERMEDAD BRONCOPULMONAR OBSTRUCTIVA CRÓNICA (EBPOC).
- COVID-19



- Enfermedad por Reflujo Gastroesofágico (ERGE)
- Influenza
- Neumonía (por cualquier causa)
- Infección por virus sincitial respiratorio (VSR)
- Infecciones respiratorias inespecíficas.

Otros exámenes paraclínicos a ser recolectados incluyen:

- Microbiología
 - Pruebas de COVID-19
 - PCR para influenza
 - Cultivo de esputo
- Hematología
 - Hematología completa
 - Prueba del dímero D.
- Bioquímica
 - Proteína C reactiva
 - Procalcitonina
 - CPK
 - LDH
 - Ferritina

Aparte de la información obtenida de la app y sus registros médicos, también le pediremos a un grupo reducido de participantes que formen parte de discusiones grupales focalizadas, para explorar los desafíos que representa el uso continuo de HyfeApp, y su participación en el estudio. En caso de que se le solicite participar, usted podrá aceptar o negarse.

Duración

Se recolectará información inicialmente por un período de 1 mes, consultándosele en ese momento su disposición a seguir participando por 3 y 6 meses. Usted podrá negarse a seguir participando en el estudio en cualquier momento.

Procedimientos del estudio

Usted no puede participar en el ensayo si:

- No puede o no quiere aceptar compartir su información codificada, relacionada a sus registros de tos con bases de datos usadas para refinar los diagnósticos basados en perfiles acústicos.
- Si tiene menos de 13 años de edad.
- Si no tiene un teléfono inteligente capaz de ejecutar HyfeApp.
- Si no es un estudiante/trabajador de la Universidad de Navarra, o un paciente diagnosticado con una enfermedad causante de tos en la Clínica Universidad de Navarra.



- 1
2
3 • Si no es residente en Navarra.
4
5

6 Si usted decide participar, un miembro de nuestro equipo lo ayudará a instalar la aplicación en su
7 móvil. No serán necesarias nuevas visitas de parte del equipo de investigación, pero serán contactados
8 una vez al mes para obtener comentarios sobre su experiencia usando la aplicación y ratificar su
9 consentimiento y disposición a seguir participando en el estudio. También podrá ser contactado vía
10 correo electrónico para recibir actualizaciones periódicas sobre el estado del proyecto y sus resultados
11 preliminares.
12
13

14 **LA APLICACIÓN HYFEAPP** 15

16
17 HyfeApp es una aplicación móvil disponible para los sistemas operativos Android y iOS (Apple),
18 desarrollada por un equipo multidisciplinario que incluye analistas de datos, desarrolladores de
19 software y médicos especialistas en enfermedades infecciosas.
20
21

22 **¿Qué hace HyfeApp?** 23

24 HyfeApp se ejecuta constantemente en el segundo plano de su móvil, sin interferir con el
25 funcionamiento de otras aplicaciones, pero teniendo acceso a su micrófono y grabando recortes de
26 sonidos explosivos de menos de 0.5 segundos de duración. Ni las conversaciones, ni los sonidos de
27 fondo son grabados. Estos recortes son enviados a un servidor, donde un algoritmo de inteligencia
28 artificial identifica aquellos que presentan cambios súbitos y cortos en los decibeles, compatibles con
29 episodios de tos. Posteriormente, otro algoritmo los procesa, evaluando otras características y
30 determinando si efectivamente se trató de un episodio de tos. El servidor envía esta información de
31 vuelta al móvil, de forma que los archivos clasificados como tos se incorporan a los registros mostrados
32 por la aplicación.
33
34

35 HyfeApp es una herramienta que le proporciona información sobre su estado de bienestar. Tal como
36 herramientas similares que cuentan calorías, registran el número de pasos o ronquidos. La única
37 diferencia es que HyfeApp cuenta episodios de tos.
38
39

40 41 **Beneficios y riesgos por su participación en estudio** 42

43 HyfeApp le permitirá llevar un registro del número de veces que tose al día, así como evidenciar
44 cambios con respecto a días anteriores. Sin embargo, no es una herramienta de diagnóstico o
45 tratamiento médico. Por lo tanto, ni provee información o consejos médicos, ni sustituye de ninguna
46 forma a los servicios sanitarios: HyfeApp no es un instrumento médico especializado. Si usted tiene
47 alguna duda sobre su estado de salud, debe consultarlas con un médico o en caso de emergencia,
48 llamar a los servicios respectivos inmediatamente .
49
50

51 Grabar sonidos desde un móvil inmediatamente genera dudas sobre la forma en que será manejada
52 la información, y garantizada la privacidad de los participantes. Como hemos explicado anteriormente,
53 HyfeApp no graba conversaciones ni sonidos de ambiente. Los segmentos de 0.5 segundos grabados
54 por la aplicación no permiten identificar a los participantes. Sin embargo, algunos de estos sonidos
55 pueden permitir identificar al participante si son interpretados en conjunto a otra metadata
56 registrada por la aplicación (como el número de teléfono, por ejemplo). Por esta razón, toda la
57
58
59
60



información transmitida por la aplicación estará encriptada y manejada según los protocolos de seguridad estándar empleados en este tipo de estudios. De esta forma, únicamente los investigadores podrán asociar los datos recolectados por la aplicación, a otros elementos que permitan identificar a los participantes.

No será remunerado por su participación en este estudio.

CONFIDENCIALIDAD

Toda la información recolectada en este estudio se mantendrá codificada, de forma que no pueda ser vinculada a sus datos personales. Solo el investigador principal y los co-investigadores sabrán su nombre y en cualquier documento o comunicación se usará un número de identificación personal asignado a cada participante. Los ordenadores utilizados para analizar los datos de este estudio tendrán contraseñas y solo investigadores autorizados podrán acceder a ellas.

La Universidad de Navarra, como responsable del tratamiento de datos, se compromete al cumplimiento de la Ley Orgánica del 3/2018, de 5 de diciembre y demás normativa de protección de datos en vigor. Por ello, es importante que conozca la siguiente información:

• Además de los derechos que ya conoce (acceso, modificación, oposición y cancelación de datos) ahora también puede limitar el tratamiento de datos que sean incorrectos, solicitar una copia o que se trasladen a un tercero (portabilidad) los datos que usted ha facilitado para el estudio. Para ejercer sus derechos, diríjase al Delegado de Protección de Datos de la institución en [\[protecciondedatosnav@unav.es\]](mailto:[protecciondedatosnav@unav.es]). Así mismo tiene derecho a dirigirse a la Agencia de Protección de Datos si no quedara satisfecho/a.

• Tanto el Centro como el Promotor son responsables respectivamente del tratamiento de sus datos y se comprometen a cumplir con la normativa de protección de datos en vigor. Los datos recogidos para el estudio estarán identificados mediante un código, de manera que no se incluya información que pueda identificarle, y sólo su médico del estudio/colaboradores podrá relacionar dichos datos con usted y con su historia clínica. Por lo tanto, su identidad no será revelada a ninguna otra persona salvo a las autoridades sanitarias, cuando así lo requieran o en casos de urgencia médica. Los Comités de Ética de la Investigación, los representantes de la Autoridad Sanitaria en materia de inspección y el personal autorizado por el Promotor, únicamente podrán acceder para comprobar los datos personales, los procedimientos del estudio clínico y el cumplimiento de las normas de buena práctica clínica (siempre manteniendo la confidencialidad de la información).

• El Investigador y el Promotor están obligados a conservar los datos recogidos para el estudio al menos hasta 25 años tras su finalización. Posteriormente, su información personal solo se conservará por el centro para el cuidado de su salud y por el promotor para otros fines de investigación científica si usted hubiera otorgado su consentimiento para ello, y si así lo permite la ley y requisitos éticos aplicables.

• Si realizáramos transferencia de sus datos codificados fuera de la UE a las entidades de nuestro grupo, a prestadores de servicios o a investigadores científicos que colaboren con nosotros, los datos del participante quedarán protegidos con salvaguardas tales como contratos u otros mecanismos por las autoridades de protección de datos. Si el participante quiere saber más al respecto, puede contactar al Delegado de Protección de Datos del promotor [\[protecciondedatosnav@unav.es\]](mailto:[protecciondedatosnav@unav.es]).



COMPENSACIÓN ECONÓMICA

El promotor del estudio es el responsable de gestionar la financiación del mismo. Para la realización del estudio, el promotor ha firmado un contrato con el centro donde se va a realizar y con el médico del estudio.

Su participación en este estudio no le causará costes adicionales diferentes de los asociados a su tratamiento habitual. La asistencia rutinaria deberá ser pagada por la seguridad social, por su seguro médico o por usted mismo.

Usted no recibirá ninguna compensación económica por su participación en este estudio.

OTRA INFORMACIÓN RELEVANTE

Cualquier nueva información referente a la aplicación utilizada en el estudio y que pueda afectar su disposición para participar en el mismo, que se descubra durante su participación, le será comunicada lo antes posible.

Si usted decide retirar el consentimiento para participar en este estudio, no se añadirán nuevos datos a la base de datos y puede exigir la destrucción de cualquier información identificable previamente retenidas para evitar la realización de nuevos análisis.

También debe saber que puede ser excluido del estudio si el promotor y/o los investigadores del estudio lo consideran oportuno, ya sea por motivos de seguridad, por cualquier acontecimiento adverso derivado de su participación, o porque consideren que no está cumpliendo con los procedimientos establecidos. En cualquiera de los casos, usted recibirá una explicación adecuada del motivo que ha ocasionado su retirada del estudio

COMPARTIENDO LOS RESULTADOS

Usted tendrá acceso a todo el conocimiento generado por esta investigación en todo momento, solo debe preguntar al investigador principal. No compartiremos su nombre, estado de salud o dirección. Eventualmente, los resultados serán publicados, de forma tal que cualquier persona interesada en conocerlos, pueda acceder a ellos. Usted podrá solicitar información sobre el estado y los resultados del estudio, preguntándole directamente al investigador principal.

Al firmar el formulario de consentimiento adjunto, se compromete a cumplir con los procedimientos del estudio que se le han expuesto.

DERECHO A NEGARSE A PARTICIPAR O ABANDONAR EL ESTUDIO

- No tiene que participar en este estudio si no desea hacerlo.
- Tiene el derecho a NO firmar este formulario. Si no desea firmar este formulario, no podrá participar en este estudio de investigación. Esto se debe a que necesitamos su permiso por escrito antes de poder usar su información.
- Tiene el derecho a abandonar este estudio incluso después de haber aceptado participar. Si decide abandonar el estudio, no usaremos su información. En caso de decidir



abandonar el estudio, por favor comuníquese con un miembro de nuestro personal. No tiene que explicar sus razones para abandonar el estudio.

A QUIÉN CONTACTAR

Si no está satisfecho con la forma en que se llevó a cabo este estudio, o tiene alguna duda, queja o pregunta sobre sus derechos como participante, por favor contacte a la oficina de atención al paciente de la Clínica Universidad de Navarra, por teléfono (+34 948 255 400) o correo electrónico (atpatientun@unav.es), para hablar con alguien independiente del equipo investigador.

Si tiene alguna duda sobre este estudio o sus procedimientos, ahora o en el futuro, puede comunicarse con: _____ . Teléfono: _____. Quién es el investigador principal del estudio. Puede llamar de lunes a viernes entre las 8:00 y las 17:00 horas.

Al firmar el formulario de consentimiento adjunto, se compromete a cumplir con los procedimientos del estudio que se le han expuesto.

Consentimiento Informado por escrito

TÍTULO DEL ESTUDIO: Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.

CÓDIGO DEL PROMOTOR:

Versión y fecha:

Yo, (nombre y apellidos)

He leído la hoja de información que se me ha entregado.

He podido hacer preguntas sobre el estudio.

He recibido suficiente información sobre el estudio.

He hablado con:

(nombre y dos apellidos del investigador)

Comprendo que mi participación es voluntaria.

Comprendo que puedo retirarme del estudio:

1º Cuando quiera



3 2º Sin tener que dar explicaciones.
4

5 3º Sin que esto repercuta en mis cuidados médicos.

7 Presto libremente mi conformidad para participar en el estudio y doy mi consentimiento para el
8 acceso y utilización de mis datos en las condiciones detalladas en la hoja de información
9

14 **Firma del investigador:**

18 **Nombre:**

21 **Fecha:**

28 **Firma del investigador:**

29 **Firma del participante:**

30 **Firma del Representante
31 legal o Testigo imparcial
32 (tácheselo lo que no proceda):**

34 **Nombre:**

35 **Nombre:**

36 **DNI:**

38 **Fecha:**

39 **Fecha:**

40 **Fecha:**

41 **A causa de:**

46 Este documento se firmará por duplicado quedándose una copia el investigador y otra el participante.
47



INFORMATION AND CONSENT SHEET

Version 3.0 (January 6th, 2021)

Study Title: Acoustic surveillance and digital cough monitoring at population level for early respiratory disease outbreak detection, an exploratory observational study

Promoter Code:

Promoter

Clinica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona

Funder: This study is funded by the Centre Hospitalier de l'Université de Montréal (CHUM) and the Patrick J. McGovern Foundation through a grant awarded to Co-Investigator Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*)

Main Researcher:

Carlos Chaccour
Teléfono +34 666 293 112
Email cchaccour@unav.es

Introduction

The objective of this document is to inform you about the characteristics of a research study you have been invited to participate in. The study has been approved by the Committee of Research Ethics of the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the ethics committee from the Centre Hospitalier de l'Université de Montréal (CHUM), in Canada.

This document aims to provide you with proper information, so you can understand this study and decide by yourself if you are willing to take part or not in it. Please read this information document carefully and we will answer any questions that might come up afterwards. You can also discuss this with people you trust before making a decision.

Voluntary Participation

You must know that your participation in this study is voluntary and you can decide not to take part, or change your mind and withdraw your consent at any time in the future. This will not affect your relationship with your healthcare provider, nor harm your access to proper medical treatment in any way.

General description of the study

Coronaviruses are a group of viruses that cause generally mild respiratory disease. However, a member of this group, the SARS-CoV-2, is responsible for causing COVID-19, a potentially dangerous disease that has spread across the globe since 2019.

One of the necessary interventions to contain the COVID-19 pandemic is understanding its real scale. This is particularly important now that new outbreaks are being regularly reported in areas with ongoing low-level transmission. A major limitation in this process is the limited diagnostic capabilities of many countries, which translates into delays in the search of medical attention and collection of necessary epidemiological data.



1
2
3
4
5
6 Most patients with COVID-19 present cough as an early symptom of disease. This study aims to
7 evaluate the usefulness of a mobile app called HyfeApp, which registers and studies cough patterns,
8 as a complement to existing disease surveillance strategies. To do this, we will need to record and
9 analyse episodes of cough in the town of Cizur Menor which has been selected as the location of the
10 initial studies of this new platform.
11

12
13 For this reason, we need as many people as possible installing the app. This App runs in the
14 background of your mobile phone. Although HyfeApp has continuous access to the mobile's mic, it
15 has been designed to exclusively process sounds that match the characteristics of human cough. When
16 one of these sounds is detected and recorded by the app, an artificial intelligence algorithm studies it
17 and determines whether it is indeed an episode of cough. If so, the record is stored, along with time
18 and geographical information provided by the mobile's GPS.
19

20
21 Besides the information from the app, we will also review the medical records of those participants
22 who present for a medical consultation in the national health system or the Clinica Universidad de
23 Navarra. The objective of this is to collect information about the presence of cough, or any respiratory
24 disease during one of those visits. Data from your medical chart will be obtained by the investigators
25 from your local clinic or hospital. This includes without being limited to information related to any of
26 the following conditions will be reviewed:
27

- 28 ● Non-specific cough
- 29 ● Non-specific upper respiratory tract infections
- 30 ● Pharyngitis
- 31 ● Asthma
- 32 ● Bronchitis
- 33 ● Chronic Obstructive Pulmonary Disease (COPD)
- 34 ● COVID-19
- 35 ● Gastro-esophageal reflux disease (GERD)
- 36 ● Influenza
- 37 ● Pneumonia (any cause)
- 38 ● Respiratory Syncytial virus
- 39 ● Non-specific respiratory tract infections

40 Additional laboratory test data to be collected from the selected visits includes:
41

- 42 ● Microbiology
 - 43 ○ COVID-19 tests
 - 44 ○ Flu PCR
 - 45 ○ Sputum culture
- 46 ● Hematology
 - 47 ○ Full blood count
 - 48 ○ D-dimer test
- 49 ● Biochemistry
 - 50 ○ C-reactive protein
 - 51 ○ Procalcitonin
 - 52 ○ CPK
 - 53 ○ LDH
 - 54 ○ Ferritin
- 55 ● Radiology



- 3 ○ Chest X-Ray
- 4 ○ Thorax CT-Scan
- 5

6 Besides the information from the app and medical charts, we will also solicit a restricted number of
7 participants to participate in focus group discussions to explore the challenges related to using
8 HyfeApp and participating in this study. If solicited, it will be your right to accept or refuse to
9 participate in those focus groups.

10 **Duration**

11 Data will be initially collected for a one-month period. You will then be offered the opportunity to
12 continue in the study for 3 and 6 months. You can refuse continuing in the study at any point.

13 **Study Procedures**

14 You will not be able to enroll in this study if you:

- 15 ● Are incapable or unwilling to accept to share your codified cough data with multicenter
16 databases aiming at refining acoustic-based diagnostics.
- 17 ● Are under 13 years of age.
- 18 ● Do not own a smartphone able to run HyfeApp.
- 19 ● Are not a student/worker at the University of Navarra or a patient diagnosed with cough-
20 related disease at the Clínica Universidad de Navarra.
- 21 ● Are not a resident in Navarra.

22 In case you decide to take part, a member of our team will help you install the app on your mobile.
23 No further visits from the research team will be necessary, but you might be contacted once a
24 month to collect feedback on your experience using the app, as well as to confirm your willingness to
25 continue in the study. You might also receive periodic updates via email, to keep you informed on
26 the status of the project and relevant preliminary results.

27 **About HyfeApp**

28 HyfeApp is a mobile app available for Android and IOS (Apple) operating systems, developed by a
29 multidisciplinary team of data scientists, software developers and infectious disease physicians.

30 **What does HyfeApp do?**

31 HyfeApp runs in the background of your mobile, without interfering with any other running app, but
32 having constant access to your mic and recording explosive sound snips of 0.5 seconds or less. No
33 conversations, nor ambient sounds are recorded. These sound snips are sent to a server, where an
34 artificial intelligence algorithm processes them, evaluating their characteristics and determining if
35 they were in fact, cough. The server then sends that data back to the mobile and the study investigator,
36 so those files labeled as cough episodes are displayed by the app. HyfeApp is a wellness status tool.
37 Just like similar apps that count calories, steps or snores. HyfeApp simply counts episodes of cough.

38 **Benefits and risks of participating**

39 HyfeApp will allow you to have a record of the number of times you cough every day, and of any
40 changes compared to previous days. However, it is not a diagnostic or treatment tool. Therefore, it
41 does not provide medical advice, nor replaces healthcare services. HyfeApp is not medical equipment.
42 If you ever have doubts regarding your health condition or status, you should consult a doctor, or in
43 case of emergency, communicate with proper emergency services.

44 We are aware that recording sounds from a mobile phone generates doubts regarding the handling
45 of information and the participants' privacy. As explained before, HyfeApp does not record
46 conversations or ambient sounds, and the 0.5 second sound snips are too short to identify



3 participants. However, if linked to other metadata (such as telephone numbers),
4 these sounds could allow identification. For this reason, all the information transmitted by the app is
5 encrypted and handled following standard safety protocols. This way, we can make sure that only the
6 researchers can access potentially identifiable data.
7

8 You will not be paid for your participation.

14 **Confidentiality**

15 All the information collected in this study will be codified in such a way that it cannot be linked to your
16 personal data. Only the principal and co-investigators involved in this study will know your name, and
17 an ID number will be used to refer to you in every document or communication. The computers used
18 to store and analyze the data will be password-protected and only authorised researchers will have
19 access to them.

22 The Universidad de Navarra, as the data controller, complies with the Organic Law 3/2018, of
23 December 5, and other Spanish data protection regulations in force. Therefore, it is important that
24 you know the following information:

- 26 • In addition to the rights that you already know (access, modification, refusal and cancellation of
27 data), you can now also limit the processing of incorrect data, request a copy, or have the data that
28 you provided be transferred to a third party (portability) for the study. To exercise your rights, contact
29 the Institution's Data Protection Officer at [protecciondedatosnav@unav.es]. You also have the right
30 to contact the Data Protection Agency if you are not satisfied.
- 33 • Both the Center and the Promoter are respectively responsible for the processing of your data and
34 undertake to comply with the data protection regulations in force. The data collected for the study
35 will be identified by a code, so that information that can identify you is not included, and only your
36 study doctor / collaborators will be able to relate said data to you and to your medical history.
37 Therefore, your identity will not be revealed to any other person except to the health authorities,
38 when required or in cases of medical emergency. The Research Ethics Committees, the
39 representatives of the Health Authority in matters of inspection and the personnel authorized by the
40 Sponsor, may only access to verify personal data, clinical study procedures and compliance with the
41 rules of good clinical practice (always maintaining the confidentiality of the information).
- 44 • The Researcher and the Sponsor are obliged to keep the data collected for the study for at least 25
45 years after its completion. Subsequently, your personal information will only be kept by the center for
46 the care of your health and by the promoter for other scientific research purposes if you have given
47 your consent to do so, and if this is allowed by the law and applicable ethical requirements.
- 50 • If we transfer your encrypted data outside the EU to our group entities, service providers or scientific
51 researchers who collaborate with us, the participant's data will be protected with safeguards such as
52 contracts or other mechanisms by the protection authorities of data. If the participant wants to know
53 more about it, he or she can contact the promoter's Data Protection Officer
54 [protecciondedatosnav@unav.es].

57 **Economic Compensation**

58 The study promoter is responsible for managing the funds. Before doing a research study, the
59 promoter must have signed a contract with the center where the study will take place, and the doctors
60



1
2
3 who will conduct the study. Your participation in this study will not cost you any
4 extra money beyond your standard medical procedures. Routine medical assistance will have to be
5 paid by the social security network, your medical insurance, or yourself.
6

7 You will not receive any payment or monetary compensation for taking part in this study.
8

9
10
11 **Other relevant information**

12 Any new information regarding the app to be used in this study and that could affect your disposition
13 to take part in it, discovered after you have decided to participate, will be communicated to you as
14 soon as possible.

15 If you wish to withdraw your consent to take part in the study, no further personal data will be added
16 to the database. You can also demand the destruction of any previously retained identifiable
17 information, to prevent new analysis from being carried on.

18 You must also know that you could be excluded from the study if the promoter and/or researchers
19 consider it to be adequate, either for your own safety, to prevent any adverse consequence deriving
20 from your participation, or because they consider you are not complying with the established
21 procedures. In any case, you will always receive a proper explanation of what caused your withdrawal
22 from the study.

23
24
25
26
27 **Sharing the results**

28 At all time, you will have access to the knowledge we get from the research upon request to the
29 principal investigator. We will not share your name, health status or where you live. After this, we will
30 publish the results so that other interested people may learn from our research. You will be able to
31 ask the status of this study and its findings by a direct request to the principal investigator.

32
33
34 **Right to refuse or withdraw**

35 You don't have to take part in this research study if you do not wish so. You have the right not to sign
36 this form. If you do not sign this form, you cannot take part in this research study. This is because we
37 need your written permission to use your information. You have the right to leave the research study.
38 If you would like to leave the research study, please tell a member of the study staff. You do not need
39 to explain why you want to leave.

40
41
42 **Who to contact?**

43 If you are not satisfied with the way this study was conducted, or if you have any concerns,
44 complaints or general questions about your rights as a participant, please contact the Patient
45 Attention Office at the Clínica Universidad de Navarra by phone (+34 948 255 400) or email
46 atpacientun@unav.es to talk with someone independent of the research team.

47
48 If you have any questions about this study or study procedures now or in the future, you can call Dr.
49 Carlos Chaccour. Tel number: 628 659 003 who is the Principal Investigator of the study. You can call
50 Monday-Friday from 8.00 to 17.00 hrs.

51
52 By signing the following informed consent, you agree to comply with the previously explained study
53 procedures.



1
2
3
4
Written informed consent form

5
6 **Study title:** Acoustic surveillance and digital cough monitoring at population level for early respiratory
7 disease outbreak detection, an exploratory observational study
8
9

10 **Promoter code**

11 Version and date:
12
13
14 I, (name and surname)
15
16
17 Have read the information sheet presented above.
18 I have been allowed to ask questions about the study.
19 I have received sufficient information about the study to make a decision.
20
21 I have spoken to:
22
23 (Name and surname of researcher)
24
25 I understand that my participation is voluntary.
26
27 I understand I can withdraw from the study:
28 1. Whenever I want to.
29 2. Without having to explain my reasons.
30 3. Without repercussions regarding my access to healthcare.
31
32
33
34 I freely and willingly accept to participate in this study. I give my consent for the access and usage of
35 my data within the conditions previously detailed in the information sheet.
36
37
38 **Researcher's signature**
39
40
41
42
43 Name:
44
45
46 Date:
47
48
49
50
51
52 Researcher's signature Participant's signature Signature of the legal
53
54
55
56
57
58
59
60
representative or impartial
witness (cross out if not
applicable)
Name: Name:: DNI:
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



1 **Date:**

2 **Date::**

3 **Date:**

4 **Reason to sign:**

5
6
7
8
9 This document will be signed in duplicate, one copy will be kept by the researcher and another one by
10 the participant.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



ID del participante:

Hoja de información y autorización a menores de entre 13 y 18 años para participar en el estudio**titulado:****Version 3.0 (6 de enero de 2021)**

Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.

Este formulario de autorización es para aquellos menores de edad dispuestos a participar en el estudio observacional previamente descrito.

Promotor

Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona.

Financiación: Este estudio está siendo financiado por el Centre Hospitalier de l'Université de Montreal (CHUM) y la fundación Patrick J. McGovern a través de una subvención otorgada al co-investigador Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*)

Investigador Principal**Carlos Chaccour****Teléfono +34 666 293 112****Email cchaccour@unav.es**

Este formulario de autorización cuenta con dos partes:

- Hoja de información (para compartir la información relevante al proyecto con usted)
- Certificado de Autorización (donde se le solicitará su firma y la de su padre, madre o representante legal, en caso de que acepte participar).

Le será proveída una copia del Certificado de Autorización.



1
2
3
4
5
6
7 **Parte I: Hoja de Información**
8

9 **Introducción**
10

11 Nos dirigimos a usted para informarle sobre un estudio de investigación en el que se le invita a
12 participar. El estudio ha sido aprobado por el Comité de Ética de la Investigación de la Universidad de
13 Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité
14 independiente de ética del Centre Hospitalier de l'Universite de Montreal (CHUM), en Canadá.
15

16
17 No es necesario que tome una decisión hoy. Puede tomarse el tiempo de hablar y discutir su
18 participación con cualquier persona con la que se sienta cómodo haciéndolo.
19

20 Con este documento pretendemos que usted reciba la información adecuada para que pueda
21 entender de qué se trata este estudio y decidir si quiere o no participar en el mismo. Es posible que
22 haya palabras o información que no entienda. De ser así, siéntase libre de preguntar cualquier duda.
23

24 **Generalidades del estudio**
25

26 Los coronavirus son un grupo de virus que causan infecciones respiratorias generalmente leves. Sin
27 embargo, un miembro de este grupo, el SARS-CoV-2, es el responsable de provocar la COVID-19, una
28 enfermedad potencialmente peligrosa que desde finales del 2019 se ha extendido a lo largo de todo
29 el mundo.
30

31 Uno de los elementos necesarios para contener el avance de la pandemia de COVID-19 es entender
32 su escala real. Esto es particularmente importante ahora que los brotes regulares en zonas en las que
33 simultáneamente ocurre transmisión a una menor escala se han convertido en una realidad. Uno de
34 los mayores obstáculos de los sistemas sanitarios es la limitada capacidad de hacer pruebas
35 diagnósticas, lo que se traduce en retrasos en la búsqueda de atención médica, así como en la
36 recolección de la información necesaria para planear intervenciones que limiten la expansión de la
37 enfermedad.
38

39 La gran mayoría de pacientes con COVID-19 presentan tos como un síntoma temprano de la
40 enfermedad. Este estudio pretende evaluar la utilidad de una aplicación para el móvil, llamada
41 HyfeApp, que registra y evalúa patrones de tos, como complemento a las estrategias de vigilancia
42 epidemiológica existentes. Para esto, estimamos que será necesario grabar y analizar al menos 15,500
43 episodios individuales de tos.
44

45 Por eso esperamos que el mayor número posible de voluntarios instale la aplicación, la cual se ejecuta
46 en segundo plano en el móvil. Aunque HyfeApp tiene acceso continuo al micrófono de su móvil, ha
47



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
sido diseñada para procesar únicamente sonidos compatibles con las características de la tos humana. Cuando uno de estos sonidos es detectado y grabado por la aplicación, un algoritmo de inteligencia artificial lo estudia y en caso de decidir qué se trata de un episodio de tos, se guarda junto a información sobre la ubicación geográfica y el momento en que ocurrió, que es proporcionada por el sistema GPS del móvil.

Aparte de la información suministrada por la aplicación, revisaremos los registros médicos de aquellas personas dispuestas a participar que acudan a consulta en el sistema nacional de salud, o la Clínica Universidad de Navarra. El objetivo de esto es recolectar información sobre la presencia de tos durante la exploración médica, o el diagnóstico de alguna enfermedad respiratoria en alguna de las visitas. Solo se consultará información relacionada con alguna de las siguientes condiciones:

- Tos no específica.
- Infecciones del tracto respiratorio superior.
- Faringitis.
- Asma.
- Bronquitis.
- Enfermedad Broncopulmonar Obstructiva Crónica (EBPOC).
- COVID-19
- Enfermedad por Reflujo Gastroesofágico (ERGE)
- Influenza
- Neumonía (por cualquier causa)
- Infección por virus sincitial respiratorio (VSR)
- Infecciones respiratorias inespecíficas.

Otros exámenes paraclínicos a ser recolectados incluyen:

- Microbiología
 - pruebas de COVID-19
 - PCR para influenza
 - Cultivo de esputo
- Hematología
 - Hematología completa
 - Prueba del dímero D.
- Bioquímica
 - Proteína C reactiva
 - Procalcitonina
 - CPK
 - LDH
 - Ferritina

Aparte de la información obtenida de la app y sus registros médicos, también le pediremos a un grupo reducido de participantes que formen parte de discusiones grupales focalizadas, para explorar los desafíos que representa el uso continuo de HyfeApp, y su participación en el estudio. En caso de que se le solicite participar, usted podrá aceptar o negarse.



Duración

Se recolectará información inicialmente por un período de 1 mes, consultándosele en ese momento su disposición a seguir participando por 3 y 6 meses. Usted podrá negarse a seguir participando en el estudio en cualquier momento.

Procedimientos del estudio

Usted no puede participar en el ensayo si usted:

- No puede o no quiere aceptar compartir su información codificada relacionada a sus registros de tos con bases de datos globales usadas para refinar los diagnósticos basados en perfiles acústicos.
- Si no posee un teléfono inteligente en el que se pueda ejecutar HyfeApp.
- Tiene menos de 13 años de edad.
- No es un estudiante/trabajador de la Universidad, o un paciente diagnosticado con una enfermedad causante de tos en la Clínica Universidad de Navarra.
- Si no reside en Navarra.

Si usted decide participar, un miembro de nuestro equipo lo ayudará a instalar la aplicación en su móvil. No serán necesarias nuevas visitas de parte del equipo de investigación, pero serán contactados una vez al mes para obtener comentarios sobre su experiencia usando la aplicación y ratificar su consentimiento y disposición a seguir participando en el estudio. También podrá ser contactado vía correo electrónico para recibir actualizaciones periódicas sobre el estado del proyecto y sus resultados preliminares.

La aplicación HyfeApp

HyfeApp es una aplicación móvil disponible para los sistemas operativos Android y iOS (Apple), desarrollada por un equipo multidisciplinario que incluye analistas de datos, desarrolladores de software y médicos especialistas en enfermedades infecciosas.

¿Qué cosas hace HyfeApp?

HyfeApp se ejecuta constantemente en el segundo plano de su móvil, sin interferir con el funcionamiento de otras aplicaciones, pero teniendo acceso a su micrófono y grabando recortes explosivos de sonido de menos de 0.5 segundos de duración. Ni las conversaciones, ni los sonidos de fondo son grabados. Estos recortes son enviados a un servidor, donde un algoritmo de inteligencia artificial identifica aquellos que presentan cambios súbitos y cortos en los decibeles, compatibles con episodios de tos. Posteriormente, otro algoritmo los procesa, evaluando otras características y determinando si efectivamente se trató de un episodio de tos. El servidor envía esta información de



vuelta al móvil, de forma que los archivos clasificados como tos se incorporan a los registros mostrados por la aplicación.

HyfeApp es una herramienta que le proporciona información sobre su estado de bienestar. Tal como herramientas similares que cuentan calorías, registran el número de pasos o ronquidos. La única diferencia es que HyfeApp cuenta episodios de tos.

12 Beneficios y riesgos por su participación en estudio

HyfeApp le permitirá llevar un registro del número de veces que tose al día, así como evidenciar cambios con respecto a días anteriores. Sin embargo, no es una herramienta de diagnóstico o tratamiento médico. Por lo tanto, ni provee información o consejos médicos, ni sustituye de ninguna forma a los servicios sanitarios: HyfeApp no es un instrumento médico especializado. Si usted tiene alguna duda sobre su estado de salud, debe consultarlas con un médico o en caso de emergencia, llamar a los servicios respectivos inmediatamente .

Grabar sonidos desde un móvil inmediatamente genera dudas sobre la forma en que será manejada la información, y garantizada la privacidad de los participantes. Como hemos explicado anteriormente, HyfeApp no graba conversaciones ni sonidos de ambiente. Los segmentos de 0.5 segundos grabados por la aplicación no permiten identificar a los participantes. Sin embargo, algunos de estos sonidos pudiesen permitir identificar al participante si son interpretados en conjunto con otra metadata registrada por la aplicación (como el número de teléfono, por ejemplo). Por esta razón, toda la información transmitida por la aplicación estará encriptada y manejada según los protocolos de seguridad estándar empleados en este tipo de estudios. De esta forma, únicamente los investigadores podrán asociar los datos recolectados por la aplicación, a otros elementos que permitan identificar a los participantes.

Usted no recibirá un pago por su participación.

41 Participación Voluntaria

Debe saber que su participación en este estudio es voluntaria y que puede decidir no participar o cambiar su decisión y retirar la autorización en cualquier momento, sin que por ello se altere la relación con su médico ni se produzca perjuicio alguno en su tratamiento.

48 Pagos y Compensación Económica

El promotor del estudio es el responsable de gestionar la financiación del mismo. Para la realización del estudio, el promotor ha firmado un contrato con el centro donde se va a realizar y con el médico del estudio.

Su participación en este estudio no le causará costes adicionales diferentes de los asociados a su tratamiento habitual. La asistencia rutinaria deberá ser pagada por la seguridad social, por su seguro médico o por usted mismo.

Ni usted ni sus padres/representantes recibirán un pago por su participación en este estudio.



Otra Información

Cualquier nueva información referente a la aplicación utilizada en el estudio y que pueda afectar su disposición para participar en el mismo, que se descubra durante su participación, le será comunicada lo antes posible.

Si usted decide retirar el consentimiento para participar en este estudio no se añadirán nuevos datos a la base de datos y puede exigir la destrucción de cualquier información identificable previamente retenida, para evitar la realización de nuevos análisis.

También debe saber que puede ser excluido del estudio si el promotor y/o los investigadores del mismo lo consideran oportuno, ya sea por motivos de seguridad, por cualquier acontecimiento adverso derivado de su participación, o porque consideren que no está cumpliendo con los procedimientos establecidos. En cualquiera de los casos, usted recibirá una explicación adecuada del motivo que ha ocasionado su retirada del estudio.

Confidencialidad

Toda la información recolectada en este estudio se mantendrá codificada, de forma que no pueda ser vinculada a sus datos personales. Solo el investigador principal y los co-investigadores sabrán su nombre y en cualquier documento o comunicación se usará un número de identificación personal asignado a cada participante. Las computadoras utilizadas para analizar los datos de este estudio tendrán contraseñas y solo investigadores autorizados podrán acceder a ellas.

La Universidad de Navarra, como responsable del tratamiento de datos, se compromete al cumplimiento de la Ley Orgánica del 3/2018, de 5 de diciembre y demás normativa de protección de datos en vigor. Por ello, es importante que conozca la siguiente información:

• Además de los derechos que ya conoce (acceso, modificación, oposición y cancelación de datos) ahora también puede limitar el tratamiento de datos que sean incorrectos, solicitar una copia o que se trasladen a un tercero (portabilidad) los datos que usted ha facilitado para el estudio. Para ejercer sus derechos, diríjase al Delegado de Protección de Datos de la institución en [protecciondedatosnav@unav.es]. Así mismo tiene derecho a dirigirse a la Agencia de Protección de Datos si no quedara satisfecho/a.

• Tanto el Centro como el Promotor son responsables respectivamente del tratamiento de sus datos y se comprometen a cumplir con la normativa de protección de datos en vigor. Los datos recogidos para el estudio estarán identificados mediante un código, de manera que no se incluya información que pueda identificarle, y sólo su médico del estudio/collaboradores podrá relacionar dichos datos con usted y con su historia clínica. Por lo tanto, su identidad no será revelada a ninguna otra persona salvo a las autoridades sanitarias, cuando así lo requieran o en casos de urgencia médica. Los Comités de Ética de la Investigación, los representantes de la Autoridad Sanitaria en materia de inspección y el personal autorizado por el Promotor, únicamente podrán acceder para comprobar los datos personales, los procedimientos del estudio clínico y el cumplimiento de las normas de buena práctica clínica (siempre manteniendo la confidencialidad de la información).



• El Investigador y el Promotor están obligados a conservar los datos recogidos para el estudio al menos hasta 25 años tras su finalización. Posteriormente, su información personal sólo se conservará por el centro para el cuidado de su salud y por el promotor para otros fines de investigación científica si usted hubiera otorgado su consentimiento para ello, y si así lo permite la ley y requisitos éticos aplicables.

• Si realizáramos transferencia de sus datos codificados fuera de la UE a las entidades de nuestro grupo, a prestadores de servicios o a investigadores científicos que colaboren con nosotros, los datos del participante quedarán protegidos con salvaguardas tales como contratos u otros mecanismos por las autoridades de protección de datos. Si el participante quiere saber más al respecto, puede contactar al Delegado de Protección de Datos del promotor [protecciondedatosnav@unav.es].

Compartiendo los Resultados

Usted tendrá acceso a todo el conocimiento generado por esta investigación en todo momento, solo debe preguntar al investigador principal. No compartiremos su nombre, estado de salud o dirección. Eventualmente, los resultados serán publicados, de forma tal que cualquier persona interesada en conocerlos, pueda acceder a ellos. Usted podrá solicitar información sobre el status y los resultados del estudio, preguntándole directamente al investigador principal.

¿Quién aprobó esta investigación?

El estudio ha sido aprobado por el Comité de Ética de la Investigación de la Universidad de Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité independiente de ética del Centre Hospitalier de l'Universite de Montreal (CHUM), en Canadá.

Derecho a negarse a participar o abandonar el estudio

- No tiene que participar en este estudio si no desea hacerlo.
- Tiene el derecho a NO firmar este formulario. Si no desea firmar este formulario, no podrá participar en este estudio de investigación. Esto se debe a que necesitamos su permiso por escrito antes de poder usar su información.
- Tiene el derecho a abandonar este estudio incluso después de haber aceptado participar. Si decide abandonar el estudio, no usaremos su información. En caso de decidir abandonar el estudio, por favor comuníquese con un miembro de nuestro personal. No tiene que explicar sus razones para abandonar el estudio.

A quién contactar

Si no está satisfecho con la forma en que se llevó a cabo este estudio, o tiene alguna duda, queja o pregunta sobre sus derechos como participante, por favor contacte a la oficina de atención al paciente de la Clínica Universidad de Navarra, por teléfono (+34 948 255 400) o correo electrónico ([attpatientun@unav.es](mailto:atpatientun@unav.es)), para hablar con alguien independiente del equipo investigador.



Si tiene alguna duda sobre este estudio o sus procedimientos, ahora o en el futuro, puede comunicarse con: Dr. Carlos Chaccour. Teléfono: 628 659 003. Quién es el investigador principal del estudio. Puede llamar de Lunes a Viernes entre las 8:00 y las 17:00 horas.

Parte II: Certificado de Autorización

Autorización del padre o representante legal

He leído o se me ha leído la información anterior. Se me permitió hacer preguntas al respecto y cualquier pregunta que haya hecho me fue contestada de forma satisfactoria.

Autorizo que mi hijo/hija o representado legal participe en este proyecto de investigación.

No autorizo que mi hijo/hija o representado legal participe en este proyecto de investigación y no he firmado la autorización presente a continuación.

Nombre del padre o representante legal:

Firma del padre o representante legal:

Fecha (dd/mm/aaaa)

Consentimiento del menor de edad

He leído o se me ha leído la información anterior. Se me permitió hacer preguntas al respecto y cualquier pregunta que haya hecho me fue contestada de forma satisfactoria.

Acepto participar en este proyecto de investigación.

No acepto participar en este proyecto de investigación y no he firmado la autorización presente a continuación.

En caso de que el menor acepte participar:

Nombre del menor de edad:

Firma del menor de edad

Fecha (dd/mm/aaaa):

En caso de no saber leer o escribir

Un testigo que sepa leer o escribir debe firmar (este individuo debería de ser posible, haber sido elegido por el participante, no su parente o representante, y no estar relacionado con el equipo de



investigación). Todo participante que no sepa leer o escribir debe presentar la huella digital de su pulgar.

Soy testigo de que este formulario fue leído de forma precisa al participante en potencia, y que dicho individuo tuvo la oportunidad para hacer preguntas. Confirmo que el individuo en cuestión ha autorizado su participación de forma voluntaria.

Nombre del testigo:

Firma del testigo:

Fecha (dd/mm/aaaa):

Huella digital del pulgar del participante:



Declaración del encargado de obtener la autorización

He leído de forma precisa la hoja de información al participante en potencia, y he hecho todo lo posible para asegurarme de que entendiera que se realizarán los siguientes procedimientos:

1. La aplicación HyfeApp deberá ser descargada en el móvil del participante.
2. La aplicación HyfeApp registrará y almacenará sonidos compatibles con la tos humana durante un período de un año, entre octubre de 2020 y septiembre de 2021.
3. En caso de acudir a una consulta en el sistema nacional de salud, la información médica del participante podrá ser accedida para buscar evidencia clínica de tos o alguna enfermedad respiratoria.

Confirmo que al participante se le ha dado la oportunidad de hacer preguntas sobre la investigación y que todas esas preguntas han sido contestadas de forma apropiada y de la mejor forma posible. Confirmo que el individuo no ha sido forzado a autorizar su participación, y que su consentimiento ha sido libre y voluntario.

Una copia de este certificado de autorización ha sido proporcionada al padre o representante legal del participante.

El padre o representante legal del participante ha firmado el consentimiento informado: Si _____
No _____

Nombre de la persona a cargo de obtener el consentimiento:



1
2 Firma de la persona a cargo de obtener el consentimiento:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Fecha (dd/mm/aaaa):

For peer review only



English version

Participant ID:

Information sheet and assent form for the participation of minors aged 13-18 years in the research study titled:Version 3.0 January 6th, 2021

Acoustic surveillance and digital cough monitoring at population level for early respiratory disease outbreak detection, an exploratory observational study

This assent form is meant for minors who are interested in taking part in the previously mentioned observational study. Please read this form carefully with your parents or legal guardian and ask any questions you might have.

Promoter

Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona.

Funder

This study is funded by the Centre Hospitalier de l'Université de Montréal (CHUM) and the Patrick J. McGovern Foundation through a grant awarded to Co-Investigator Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*)

Main Researcher

Carlos Chaccour
Teléfono +34 666 293 112
Email cchaccour@unav.es

This document consists of two parts:

- Information sheet (meant to explain relevant information regarding the project).
- Assent form (where we will require your signature, and that of your parent or legal guardian, if you decide to take part in it).

You will be provided a copy of this document for your personal records.



1
2
3
4
Part I: Information sheet
5

6
Introduction
7

8
9
10
11
12
The objective of this document is to inform you about the characteristics of a research study you have
13
been invited to participate in. The study has been approved by the Committee of Research Ethics of
14
the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the
15
independent ethics committee from the Centre Hospitalier de l'Université de Montreal (CHUM), in
16
Canada.
17

18
This document aims to provide you with proper information, so you can understand this study and
19
decide by yourself if you are willing to take part or not in it. Please read this information document
20
carefully and we will answer any questions that might come up afterwards. You can also discuss this
21
with people you trust before making a decision.
22

23
Objective of the research
24

25
Coronaviruses are a group of viruses that cause generally mild respiratory disease. However, a
26
member of this group, the SARS-CoV-2, is responsible for causing COVID-19, a potentially dangerous
27
disease that has spread across the globe since 2019.
28

29
One of the necessary interventions to contain the COVID-19 pandemic is understanding its real scale.
30
This is particularly important now that new outbreaks are being regularly reported in areas with
31
ongoing low-level transmission. A major limitation in this process is the limited diagnostic capabilities
32
of many countries, which translates into delays in the search of medical attention and the collection
33
of necessary epidemiological data.
34

35
Most patients with COVID-19 present cough as an early symptom of disease. This study aims to
36
evaluate the usefulness of a mobile app called HyfeApp, which registers and studies cough patterns,
37
as a complement to existing disease surveillance strategies. To do this, we will need to record and
38
analyse about 15,500 individual episodes of cough. The town of Cizur Menor has been selected as the
39
location of the initial studies of this new platform.
40

41
For this reason, we need as many people as possible installing the app, which runs in the background
42
of your mobile. Although HyfeApp has continuous access to the mobile's mic, it has been designed to
43
exclusively process sounds that match the characteristics of human cough. When one of these sounds
44
is detected and recorded, an artificial intelligence algorithm studies it and where it determines it does
45
sound like an episode of cough, the record is stored, along with geographical information and time,
46
provided by the mobile's GPS.
47

48
Besides the information from the app, we will also review the medical records of those participants
49
who present for a medical consultation in the national health system or the Clinica Universidad de
50
Navarra. The objective of this is to collect information about the presence of cough, or any respiratory
51
disease during one of those visits. Data from your medical chart will be obtained by the investigators
52
from your local clinic or hospital. This includes without being limited to information related to any of
53
the following conditions will be reviewed:
54

- 55 ● Non-specific cough
- 56 ● Non-specific upper respiratory tract infections
- 57 ● Pharyngitis
- 58 ● Asthma
- 59 ● Bronchitis



- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19
- Gastro-esophageal reflux disease (GERD)
- Influenza
- Pneumonia (any cause)
- Respiratory Syncytial virus
- Non-specific respiratory tract infections

Additional laboratory test data to be captured from the selected visits includes:

- Microbiology
 - COVID-19 tests
 - Flu PCR
 - Sputum culture
- Hematology
 - Full blood count
 - D-dimer test
- Biochemistry
 - C-reactive protein
 - Procalcitonin
 - CPK
 - LDH
 - Ferritin

Besides the information from the app and medical charts, we will also solicit a restricted number of participants to participate in focus group discussions to explore the challenges related to using HyfeApp and participating in this study. If solicited, it will be your right to accept or refuse to participate in those focus groups.

Duration

Data will be initially collected for a one-month period. You will then be offered the opportunity to continue in the study for 3 and 6 months. You can refuse continuing in the study at any point.

Study Procedures

You will not be able to enroll in this study if you:

- Are incapable or unwilling to accept to share your codified cough data with multicenter databases aiming at refining acoustic-based diagnostics.
- Are under 13 years of age.
- Do not own a smartphone able to run HyfeApp.
- Are not a student/worker at the University of Navarra or a patient diagnosed with cough-related disease at the Clínica Universidad de Navarra.
- Are not a resident of Navarra

In case you decide to take part, a member of our team will help you install the app on your mobile. No further visits from the research team will be necessary. But you might be contacted once a month to collect feedback on your experience using the app, as well as to confirm your willingness to continue in the study. You might also receive periodic updates via email, to keep you informed on the status of the project and relevant preliminary results.

About HyfeApp



HyfeApp is a mobile app available for Android and IOS (Apple) operative systems, developed by a multidisciplinary team of data scientists, software developers and infectious disease physicians.

What does HyfeApp do?

HyfeApp runs in the background of your mobile, without interfering with any other running app, but having constant access to your mic and recording explosive sound snips of 0.5 seconds or less. No conversations, nor ambient sounds are recorded. These sound snips are sent to a server, where an artificial intelligence algorithm identifies those presenting sudden, shortchanges in decibel levels, compatible with cough episodes. Then, another algorithm processes them, evaluating its characteristics and determining if they were in fact, cough. The server then sends that data back to the mobile, so those files labeled as cough episodes are displayed by the app. HyfeApp is a wellness status tool. Just like similar apps that count calories, steps or snores. The only difference is that HyfeApp counts episodes of cough.

Benefits and risks of participating

HyfeApp will allow you to have a record of the number of times you cough every day, and of any changes compared to previous days. However, it is not a diagnostic or treatment tool. Therefore, it does not provide medical advice, nor replaces healthcare services. HyfeApp is not medical equipment. If you ever have doubts regarding your health condition or status, you should consult a doctor, or in case of emergency, communicate with proper emergency services.

We are aware that recording sounds from a mobile phone generates doubts regarding the handling of information and the participants' privacy. As explained before, HyfeApp does not record conversations or ambient sounds, and the 0.5 second sound snips are too short to identify participants. However, if linked to other metadata (such as telephone numbers), these sounds could allow identification. For this reason, all the information transmitted by the app is encrypted and handled following standard safety protocols. This way, we can make sure that only the researchers can access potentially identifiable data.

You will not be paid for your participation.

Voluntary participation

You must know that your participation in this study is voluntary and you can decide not to take part, or change your mind and resign your consent at any time in the future. This will not affect your relationship with your healthcare provider, nor harm your access to proper medical treatment in any way.

Economic Compensation

The study promoter is responsible for managing the funds. Before, doing a research study, the promoter must have signed a contract with the center where the study will take place, and the doctors who will conduct the study. Your participation in this study will not cost you any extra money beyond your standard medical procedures. Routine medical assistance will have to be paid by the social security network, your medical insurance, or yourself.



You will not receive any payment or monetary compensation for taking part in this study.

Other information

Any new information regarding the app to be used in this study and that could affect your disposition to take part in it, discovered after you have decided to participate, will be communicated to you as soon as possible.

If you wish to withdraw your consent to take part in the study, no further personal data will be added to the database. You can also demand the destruction of any previously retained identifiable information, to prevent new analysis from being carried on.

You must also know that you could be excluded from the study if the promoter and/or researchers consider it to be adequate, either for your own safety, to prevent any adverse consequence deriving from your participation, or because they consider you are not complying with the established procedures. In any case, you will always receive a proper explanation of what caused your withdrawal from the study.

Confidentiality

All the information collected in this study will be codified in such a way that they cannot be linked to your personal data. Only the main researcher and co-researchers will know your name, and an ID number will be used to refer to you in every document or communication. The computers used to store and analyse the data will be password-protected and only authorised researchers will have access to them.

The Clínica Universidad de Navarra, as the data controller, complies with the Organic Law 3/2018, of December 5, and other Spanish data protection regulations in force. Therefore, it is important that you know the following information:

• In addition to the rights that you already know (access, modification, refusal and cancellation of data), you can now also limit the processing of incorrect data, request a copy, or have the data that you provided be transferred to a third party (portability) for the study. To exercise your rights, contact the Institution's Data Protection Officer at [protecciondedatosnav@unav.es]. You also have the right to contact the Data Protection Agency if you are not satisfied.

• Both the Center and the Promoter are respectively responsible for the processing of your data and undertake to comply with the data protection regulations in force. The data collected for the study will be identified by a code, so that information that can identify you is not included, and only your study doctor / collaborators will be able to relate said data to you and to your medical history. Therefore, your identity will not be revealed to any other person except to the health authorities, when required, or in cases of medical emergency. The Research Ethics Committees, the representatives of the Health Authority in matters of inspection and the personnel authorized by the Sponsor, may only access to verify personal data, clinical study procedures and compliance with the rules of good clinical practice (always maintaining the confidentiality of the information).

• The Researcher and the Sponsor are obliged to keep the data collected for the study for at least 25 years after its completion. Subsequently, your personal information will only be kept by the center for



the care of your health and by the promoter for other scientific research purposes if you have given your consent to do so, and if this is allowed by the law and applicable ethical requirements.

- If we transfer your encrypted data outside the EU to our group entities, service providers or scientific researchers who collaborate with us, the participant's data will be protected with safeguards such as contracts or other mechanisms by the protection authorities of data. If the participant wants to know more about it, he or she can contact the promoter's Data Protection Officer [protecciondedatosnav@unav.es].

Sharing the results

At all time, you will have access to the knowledge we get from the research upon request to the principal investigator. We will not share your name, health status or where you live. After this, we will publish the results so that other interested people may learn from our research. You will be able to ask the status of this study and its findings by a direct request to the principal investigator.

Who approved this research?

The study has been approved by the Committee of Research Ethics of the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the independent ethics committee from the Centre Hospitalaire de l'Université de Montreal (CHUM), in Canada.

Right to refuse or withdraw

You don't have to take part in this research study if you do not wish so. You have the right not to sign this form. If you do not sign this form, you cannot take part in this research study. This is because we need your written permission to use your information. You have the right to leave the research study. If you would like to leave the research study, please tell a member of the study staff. You do not need to explain why you want to leave.

Who to contact?

If you are not satisfied with the way this study was conducted, or if you have any concerns, complaints or general questions about your rights as a participant, please contact the Patient Attention Office at the Clínica Universidad de Navarra by phone (+34 948 255 400) or email atpacientun@unav.es to talk with someone independent of the research team.

If you have any questions about this study or study procedures now or in the future, you can call Dr. Carlos Chaccour. Tel number 628 659 003 who is the Principal Investigator of the study. You can call Monday-Friday from 8.00 to 17.00 hrs.

Part II: Assent Form

Authorization from the parent or legal guardian

I have read, or have been read to the previous information. I was allowed to ask questions and I was provided with satisfactory answers to each one.

I authorize my child/minor under my care to take part in this research project.



1
2
3 I do not authorize my child/minor under my care to take part in this
4 research project and I have not signed the Assent Form presented below.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Name of parent or legal guardian:

Signature of parent or legal guardian:

Date (dd/mm/yyyy):

Consent from the minor

I have read or have been read to the previous information. I was allowed to ask questions and I was provided with satisfactory answers to each one.

I accept to take part in this research project.

I do not accept to take part in this research project and I have not signed the assent form presented below.

In case the minor accepts to participate:

Name of minor:

Signature of minor:

Date (dd/mm/yyyy):

If illiterate:

A literate witness must sign this form (when possible, this person should be chosen by the participant and not be related to the research team). Every illiterate participant must still present a fingerprint of his/her thumb.

I confirm this form was properly and accurately read to the potential participant and that said individual has voluntarily consented to participate in the study.

Name of witness:

Signature of witness:

Date (dd/mm/yyyy):

Participant's fingerprint (thumb):

A large, empty rectangular box intended for the participant's fingerprint.

Statement from the person responsible of getting written consent



I have, to the best of my ability, read this information sheet to the potential participant and made my best effort to make sure he/she understood that the following procedures will be performed:

1. HyfeApp will be downloaded to the participant's mobile phone.
2. HyfeApp will register and store sounds that match the characteristics of human cough for a one-year period, between October 2020 and September 2021.
3. If the participant seeks medical attention through the national health network, his/her medical records could be accessed by the researchers to look for evidence of cough or any respiratory disease.

I confirm the participant has been allowed to ask questions and that all his/her questions have been answered to the best of my ability. I confirm the participant has not been coerced to take part in this study and that his consent was free and voluntary.

A copy of this form will be provided to the parent or legal guardian for personal records.

Has the parent or legal guardian signed the assent form?: Yes No

Name of the person in charge of obtaining the participant's consent:

Signature of the person in charge of obtaining the participant's consent:

Date (dd/mm/yyyy):

**Cuestionario complementario de información médica****Versión 2.0 (6 de enero, 2021)****Información personal**

Nombre: _____

Primer Apellido: _____

Segundo Apellido: _____

Fecha de nacimiento: _____

DNI: _____

Sistema operativo del móvil:

- Apple
- Android

Ciudad o pueblo _____ Avenida/Calle _____

Número _____ Escalera (izquierda o derecha, solo para departamentos) _____

Piso _____ Puerta _____

¿Usualmente usted recibe atención médica a través de cuál de los siguientes proveedores de salud?

- Público (Seguridad Social/Osasunbidea)
- Privado (Clínica Universidad de Navarra)
- Ambos

¿Ha sufrido usted de alguna de las siguientes condiciones en el pasado, o sufre de alguna en la actualidad?

- Tos de causa no específica o desconocida
- Infecciones no especificadas de las vías respiratorias altas (Sinusitis, otitis, laringitis)
- Faringitis
- Asma
- Bronquitis
- Enfermedad broncopulmonar obstructiva crónica (EBPOC)
- COVID-19
- Enfermedad de Reflujo Gastroesofágico (ERGE)
- Influenza estacional



- Neumonía (sin importar la causa)
- Infección por virus sincitial respiratorio
- Otras infecciones no especificadas del tracto respiratorio inferior
- Fumador
- Otra condición

En caso de haber seleccionado la
_____ v _____
explique a continuación a que se
refiere:



English version

Medical Information Questionnaire for participants recruited at the University of Navarra

Version 2.0 (January 6th, 2021)

The following information must be filled by participants who have consented to take part in the study

Participant information

Name: _____

First surname: _____

Second surname: _____

DOB: _____

DNI: _____

Apple

Android

Residence city _____ Street _____

Street

Number _____ **Stair (left or right, only for apartment buildings)** _____

Floor Door

Usually, you receive medical care from which of the following providers?

- Public health network (Social Security/Osasunbidea)
 - Private (Clínica Universidad de Navarra)
 - Both

Please indicate if you have suffered from any of the following medical conditions



- 1 Non-specific cough
- 2 Non-specific upper respiratory tract infections
- 3 Acute pharyngitis
- 4 Asthma
- 5 Bronchitis
- 6 Chronic Obstructive Pulmonary Disease (COPD)
- 7 COVID-19
- 8 Gastroesophageal Reflux Disease (GERD)
- 9 Influenza
- 10 Pneumonia (any cause)
- 11 Respiratory Syncytial Virus Disease
- 12 Another non-specific lower respiratory tract infection
- 13 Smoker
- 14 Other condition (please specify): _____
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	
		Digital Acoustic Surveillance for Respiratory Disease Outbreak Early Detection: An Exploratory Observational Study in Navarra, Spain	

Administrative information

Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	✓
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p. 3
	2b	All items from the World Health Organization Trial Registration Data Set	NA
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	p. 19
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p. 0
	5b	Name and contact information for the trial sponsor	p. 0
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	p. 19
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	p.5-6
	6b	Explanation for choice of comparators	NA
Objectives	7	Specific objectives or hypotheses	p. 8
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p.6-7

Methods: Participants, interventions, and outcomes

- Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained p. 6
- Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) p. 8
- Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered p.9-10,11
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) NA
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) p. 9
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial NA
- Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended p. 12-15
- Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) p. 7-8, Figure 1
- Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations p. 12
- Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size p. 7

Methods: Assignment of interventions (for controlled trials)

Allocation:

- Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions NA

- 1 Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned NA
- 2 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions p. 7
- 3 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how NA
- 4 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial NA

Methods: Data collection, management, and analysis

- Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol p. 7, 12-15.
- 30 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols p. 9
- Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol p.15-16
- Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol p. 12-15
- 44 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) p. 15
- 48 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) NA

Methods: Monitoring

- Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed NA

1	21b	Description of any interim analyses and stopping guidelines, including 3 who will have access to these interim results and make the final 4 decision to terminate the trial NA
5	Harms	22 Plans for collecting, assessing, reporting, and managing solicited and 6 spontaneously reported adverse events and other unintended effects 7 of trial interventions or trial conduct p. 15
8	Auditing	23 Frequency and procedures for auditing trial conduct, if any, and 9 whether the process will be independent from investigators and the 10 sponsor NA
11	12	13
14	15	16

Ethics and dissemination

17	Research ethics approval	24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval p. 16
18	Protocol amendments	25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) p. 16
19	Consent or assent	26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) p. 7
20		26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable NA
21	Confidentiality	27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial p. 15-16
22	Declaration of interests	28 Financial and other competing interests for principal investigators for the overall trial and each study site p. 19
23	Access to data	29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators Data share agreement included in the research agreement, but not included in the submission.
24	Ancillary and post-trial care	30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation NA
25	Dissemination policy	31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions p. 16
26		31b Authorship eligibility guidelines and any intended use of professional writers p. 19
27		31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code NA
28	29	30
31	32	33
34	35	36
37	38	39
40	41	42
43	44	45
46	47	48
49	50	51
52	53	54
55	56	57
58	59	60

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates Yes
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks in Spain: A protocol for an observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051278.R1
Article Type:	Protocol
Date Submitted by the Author:	27-May-2021
Complete List of Authors:	Gabaldon-Figueira, Juan; Clínica Universidad de Navarra, Área de Enfermedades Infecciosas Brew, Joe; Hyfe Inc Doré, Dominique; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Immunopathology Axis Umashankar, Nita; San Diego State University Chaccour, Juliane ; Clínica Universidad de Navarra, Área de Enfermedades Infecciosas Orrillo, Virginia; University of Navarra, School of Pharmacy and Nutrition Tsang, Lai Yu; Stony Brook University, Global Health Institute Blavia, Isabel; University of Navarra, School of Pharmacy and Nutrition Fernández-Montero , Alejandro ; Clínica Universidad de Navarra Bartolomé, Javier; Servicio Navarro de Salud - Osasunbidea Grandjean Lapierre, Simon; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Immunopathology Axis; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Department of Microbiology, Infectious Diseases and Immunology Chaccour, C; Universitat de Barcelona, ISGlobal; Clínica Universidad de Navarra, Area of Infectious Diseases
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	COVID-19, Respiratory infections < THORACIC MEDICINE, Epidemiology < TROPICAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2 **Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks in Spain:**
3 **A protocol for an observational study**

4 Juan C. Gabaldón-Figueira^{a*} [jgabaldonfi@unav.es] (ORCID: 0000-0002-2525-0263)

5 Joe Brew^b [joe@hyfe.ai] (ORCID: 0000-0002-4119-0117)

6 Dominique Hélène Doré^c [dominique.helene.dore@umontreal.ca]

7 Nita Umashankar^d [numashankar@sdsu.edu]

8 Juliane Chaccour^a [jchaccour@gmail.com] (ORCID: 0000-0001-5611-9690)

9 Virginia Orrillo^e [vorrillo@alumni.unav.es]

10 Lai Yu Tsang^f [Lai.Tsang@stonybrookmedicine.edu]

11 Isabel Blavia^e [iblavia@alumni.unav.es]

12 Alejandro Fernandez-Montero^a [afmontero@unav.es]

13 Javier Bartolomé^g [fjbr@medena.es]

14 Simon Grandjean Lapierre^{c,i} †

15 [simon.grandjean.lapierre@umontreal.ca] (ORCID 0000-0003-3646-1573)

16 Carlos Chaccour^{h, a, j} † [carlos.chaccour@isglobal.org] (ORCID 0000-0001-9812-050X)

17

18 *Corresponding author

19 †These authors contributed equally

20 **Corresponding author's contact information**

21 Juan C. Gabaldón-Figueira

22 E: jgabaldonfi@unav.es

23 Address: Av. Pío XII, 36, Pamplona, Navarra, Spain. 31008.

24

25 **Affiliations**

26 ^a Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain

1
2
3 **27** ^b Hyfe Inc, Wilmington, DE, USA
4
5 **28** ^c Immunopathology Axis, Centre de Recherche du Centre Hospitalier de l'Université de
6
7 **29** Montréal, Montréal, Québec, Canada
8
9 **30** ^d San Diego State University, San Diego, CA, USA
10
11 **31** ^e School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
12
13 **32** ^f Stony Brook University, Global Health Institute, Stony Brook, New York, USA
14
15 **33** ^g Servicio Navarro de Salud- Osasunbidea, Zizur Mayor, Spain
16
17 **34** ^h ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain
18
19 **35** ⁱ Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal,
20
21
22 **36** Montréal, Québec, Canada
23
24 **37** ^jIfakara Health Institute, United Republic of Tanzania.
25
26
27 **38**
28
29
30 **39** **Word count:** 3471
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **40 Abstract**

3 **41 Introduction**

4 Cough is a common symptom of COVID-19 and other respiratory illnesses. However,
5 objectively measuring its frequency and evolution is hindered by the lack of reliable and
6 scalable monitoring systems. This can be overcome by newly developed artificial intelligence
7 models that exploit the portability of smartphones. In the context of the ongoing COVID-19
8 pandemic, cough detection for respiratory disease syndromic surveillance represents a simple
9 means for early outbreak detection and disease surveillance. In this protocol, we evaluate the
10 ability of population-based digital cough surveillance to predict the incidence of respiratory
11 diseases at population level in Navarra, Spain, while assessing individual determinants of
12 uptake of these platforms.

13 **51 Methods and analysis**

14 Participants in the Cendea de Cizur, Zizur Mayor, or attending the local University of Navarra
15 (Pamplona) will be invited to monitor their night-time cough using the smartphone app Hyfe
16 Cough Tracker™. Detected coughs will be aggregated in time and space. Incidence of
17 COVID-19, and other diagnosed respiratory diseases within the participants cohort, and the
18 study area and population will be collected from local health facilities and used to carry out
19 an ARIMA analysis on those independent time series. In a mixed-methods design, we will
20 explore barriers and facilitators of continuous digital cough monitoring by evaluating
21 participation patterns, socio demographic characteristics. Participants will fill an
22 acceptability questionnaire and a subgroup will participate in focus group discussions.

23 **61 Ethics and dissemination**

24 Ethics approval was obtained from the ethics committee of the Centre Hospitalier de
25 l'Université de Montréal, Canada and the Medical Research Ethics Committee of Navarre,
26 Spain. Preliminary findings will be shared with civil and health authorities and reported to

1
2
3 65 individual participants. Results will be submitted for publication in peer-reviewed scientific
4
5 66 journals and international conferences.
6
7
8 67 **Trial Registration Number**
9
10 68 clinicaltrials.gov/NCT04762693
11
12 69
13
14 70
15
16 71
17
18 72
19
20 73
21
22 74
23
24 75
25
26 76
27
28 77
29
30 78
31
32 79
33
34 80
35
36 81
37
38 82
39
40 83
41
42 84
43
44 85
45
46 86
47
48 87
49
50 88
51
52 89
53
54 90

For peer review only

1
2
3 **91 Strengths and limitations of this study**

4
5 92 1. This is the first study to evaluate the utility of artificial intelligence models and
6 93 smartphone applications for cough detection at population level.

7
8
9 94 2. The studied approach has the potential to be rapidly scalable even within
10 95 underdeveloped public health systems.

11
12
13 96 3. Qualitative methods will improve the understanding of barriers and facilitators
14 97 affecting the uptake of cough detection smartphone applications and participation in acoustic
15 98 surveillance programs.

16
17
18 99 4. Recorded coughs will be annotated with clinical diagnoses (when available) and will
19 100 contribute to the training of cough-based disease-specific screening and diagnostic tools.

20
21 101 5. Success of this study is contingent on large-scale enrolment and high participant
22 102 retention since a small sample size might not be sufficient to appropriately correlate the study
23 103 population's cough trends and their relationship with the incidence of respiratory diseases at
24
25 104 population level.

1
2
3 105 **Introduction**
4
5

6 106 Real-time tracking of the COVID-19 pandemic and detection of the emergence of novel
7 107 variants or other respiratory pathogens represent challenges for public health authorities
8
9

10 108 globally. Nonetheless, understanding local epidemiology is essential to disease control efforts.
11
12

13 109 This is particularly true now that the world has moved into a COVID-19 endemic phase, with
14 110 periodic outbreaks in multiple locations superimposed over ongoing community transmission.
15
16

17 111 The ability to appropriately monitor disease incidence, however, is frequently limited by a lack
18 112 of testing capacity, delays in health-seeking behaviours, as well as complexities related to
19 113 timely aggregation of actionable surveillance data by public health authorities.
20
21

22 114 Although asymptomatic cases of COVID-19 and other respiratory communicable diseases are
23 115 well described, cough remains a common symptom of COVID- 19 (1, 2). A meta-analysis
24 116 including data from over 24,000 adults with confirmed COVID-19 revealed cough as the
25 117 second most prevalent symptom, being reported by 57% (CI: 54-60%) of all patients. (3)
26
27

28 118 Additionally, cough is a key event in the transmission of COVID-19 and other respiratory
29 119 pathogens.(4)
30
31

32 120 Given the intrinsic subjectivity of existing cough monitoring tools, mostly based in self-
33 121 reported questionnaires, there is a great interest in developing an automated system to
34 122 objectively register coughs. Attempts to achieve this date back to the 1950s, but until recently,
35 123 important technologic constraints limited significant advances. (5)
36
37

38 124 Even now, detecting and classifying sounds as coughs without the input of a human observer,
39 125 still represents a remarkable challenge. However, automatically detecting cough is now
40 126 possible thanks to the development of acoustics and artificial intelligence (AI) models which
41 127 can be incorporated into wearable devices. This has allowed the development of several
42 128 alternatives, whose widespread deployment beyond a research context remains limited due
43 129 to problems related to portability, the need to continuously record sound (which may
44
45

1
2
3 130 compromise patients' privacy), inconsistent sensitivity and specificity, high false positivity
4 131 rates, and little financial incentives.(5)

5
6 132
7
8 133 Some of these limitations might be addressed by incorporating similar systems on smartphone
9 134 applications, an approach that has just recently begun to be widely explored.(6, 7) In brief,
10 135 putative cough sounds (manifested as short and explosive noises) are recognized and
11 136 captured by smartphones. Machine learning models trained on hundreds of thousands of
12 137 annotated sounds are then used to distinguish cough from other sounds.

13 138 We propose that COVID-19 surveillance and early outbreak recognition can be enhanced by
14 139 digitally monitoring cough and detecting changes in its incidence at population level. We
15 140 hypothesize such changes precede individual symptoms recognition, healthcare seeking
16 141 behaviours, diagnosis, and data aggregation within conventional disease surveillance systems.

17 142 Indeed, digital cough monitoring data can be aggregated in real time providing constantly
18 143 updated information on the emergence and activity of communicable respiratory diseases
19 144 within populations. This approach would be of particular value in low- and middle-income
20 145 countries where (a) capturing passive data through health services is insufficient given
21 146 unequal access to healthcare, and (b) active case detection and contact tracing capacity is
22 147 limited. (8, 9)

23 148 To our knowledge, digital cough monitoring for early detection of respiratory disease
24 149 outbreaks has never been performed. Provided the participation of a critical mass of active
25 150 users is achieved, monitoring of aggregated cough data could provide a simple and
26 151 inexpensive surrogate indicator for overall respiratory infections incidence, similar to, but
27 152 more accurate than wastewater monitoring (10). This information could in turn guide public
28 153 health interventions. If proven successful in the specific case of COVID-19, this study would
29 154 establish a template for early and disease-agnostic detection of emerging pathogens,
30 155 therefore contributing to health systems epidemic preparedness.

1
2
3 156 **Primary research question**
4
5 157 Can digital cough surveillance predict the incidence of respiratory diseases at population-level
6
7 158 in Navarra, Spain?
8
9
10 159
11
12 160 **Methods**
13
14 161 **Study design**
15
16 162 This is a prospective observational study which will take place between November 2020 and
17
18 163 October 2021 (Figure 1). Participants will be recruited in (a) the Cendea de Cizur, a
19
20 164 municipality composed by a cluster of villages south of the city of Pamplona, (b) the
21
22 165 neighbouring town of Zizur Mayor, in the Chartered Community of Navarra (Spain), as well as
23
24 166 (c) in the different campuses of the University of Navarra (Pamplona), which collides with the
25
26 167 municipalities.
27
28
29
30 168 All these communities are located within a 5 km range from each other, and there is a
31
32 169 considerable geographical and social overlap between them, as the University of Navarra is
33
34 170 the second most important employer in the area.
35
36
37 171 The 4,000 people living in the Cendea de Cizur are served by a public health center which
38
39 172 receives 45,000 outpatients visits per year. Of these, approximately 12% are associated with
40
41 173 respiratory diseases. Furthermore, the Clínica Universidad de Navarra is the main private
42
43 174 healthcare provider in the region and offers medical care to a significant proportion of the
44
45 175 population, as well as university students and workers. Both centres offer COVID-19 PCR
46
47 176 testing. Together, those two healthcare facilities cover most of the population's healthcare
48
49 177 needs and have digitalized medical record systems that facilitate the retrieval of medical data
50
51 178 concerning the diagnosis of respiratory diseases among participants.
52
53
54 179 Recruitment strategies will include direct solicitation, community meetings, videos and
55
56 180 advertisements in social media and university communication platforms. Those willing to
57
58 181 participate will attend individual sessions with a study coordinator for counselling and training
59
60

1
2
3 182 using the Hyfe Cough Tracker™ (Hyfe™) application, and for obtention of informed consent.
4
5 183 Information consent forms for adults and minors are available as supplementary material 1,
6
7 184 and supplementary material 2, respectively. Participants will consent to be contacted
8
9 regularly via email and telephone by the study team and will also fill an enrolment
10
11 185 questionnaire (Supplementary material 3) where demographic and respiratory diseases
12
13 186 medical data will be collected.
14
15
16 188
17
18 189 **Primary objective**
19
20 190 1. To assess the value of digital cough monitoring and acoustic surveillance in predicting
21
22 191 COVID-19 and other respiratory diseases incidence at population level.
23
24
25 192 **Secondary objective**
26
27 193 2. To assess barriers and facilitators to participation in an acoustic surveillance program
28
29 194 using a smartphone-based digital cough monitoring application.
30
31
32 195
33
34
35 196 **Eligibility criteria**
36
37 197 To be included in the study, participants must (i) be 13 years old or older, (ii) own a
38
39 198 smartphone, (iii) be willing to install and use the Hyfe™ digital cough monitoring application,
40
41 199 (iv) accept and comply with Hyfe™ privacy policy and terms of use, and (v) grant access to
42
43 200 their medical records. To optimize population representativity, participants also need to (vi)
44
45 201 visit the University of Navarra on a regular basis, either as a student, worker, or patient of the
46
47 202 university clinic, or (vii) have a general interest in the study, and (viii) currently reside in
48
49 203 Navarra. These criteria aim at ensuring a large sample size and the availability of needed
50
51 204 medical records while concentrating recruitment in a geographically focused area. Accounting
52
53 205 for differences between smartphone models' capabilities, upon recruitment, participants will
54
55 206 also have to complete a microphone calibration process within the application. This is to make
56
57
58
59
60

1
2
3 207 sure their smartphones can accurately detect cough-like sounds. Participants who fail to
4
5 208 complete this process will be excluded from the study.
6
7
8 209 **Participant retention**
9
10

11 210 To ensure participants' retention and promote continuous cough recording, we will use videos
12 211 posted on social media, as well as emailed to participants, text messages and regular push
13 212 notifications sent via the Hyfe™ application on participants' smartphones. Participants will
14 213 also receive monthly emails with information regarding the current stage of the study and
15 214 high-level preliminary results.
16
17
18
19
20
21
22

23 215
24
25 216 **Digital cough monitoring**
26 217 The cough detection application used in this study is Hyfe Cough Tracker™ (Hyfe™).
27
28 218 (<https://www.hyfeapp.com/>). Hyfe™ runs in the background of smartphones operating
29 systems, listens for and records short snippets (<0.5 seconds) of explosive, putative cough
30
31 220 sounds and then classifies them as cough or non-cough, using a convolutional neural network
32
33 221 model. Cough sounds are automatically matched with time and GPS coordinates which can be
34
35 222 jittered to ensure participants' privacy. Hyfe™ is a research tool that has collected over 5
36
37 223 million putative cough sounds, of which over 1,000,000 have been classified as coughs or not
38
39 224 by a human listener in order to train the AI model.
40
41
42

43
44 225 The analytical performance of Hyfe™ for cough detection (referred to whether the application
45
46 226 is sensitive and specific for the classification of recorded sounds as coughs or non-coughs) was
47
48 227 confirmed using this study's preliminary results from a subgroup of participants recruited in
49
50 228 the Cendea de Cizur between November and December 2020.
51
52

53
54 229 Approximately 500 participants were contacted from an existing mailing list used in a previous
55
56 230 epidemiological study, of these, 57 were enrolled. While participants were initially requested
57
58 231 to keep Hyfe™ running continuously, they were later instructed to restrict their use to at least
59
60

1
2 232 6 hours during night-time, for 30 days, following complaints of increased battery
3 consumption.
4
5

6
7 234 During this period, nearly 700,000 putative cough sounds were registered, of which 119,876
8 were classified by human observers, revealing a sensitivity of 96.34% and a specificity of
9 235
10 236 96.54%, when using a cough-positivity threshold of 0.85 (Figure 2).
11
12

13 237 These values, however, must be interpreted carefully, as specificity measured at the explosive
14 sound level does not necessarily provide a full picture of diagnostic accuracy, particularly in
15 loud environments, where the probability of an explosive sound being a cough is lower, and
16 the false positivity rate might be considerably higher. Similarly, sensitivity does not account
17 for non-explosive sounds, that are not captured by the system, and of which a non-zero
18 number might be coughs.
19
20

21 243 Upon enrolment, a study coordinator will assist participants in installing the Hyfe™
22 application. Once turned on, it will continuously monitor participants' cough. Participants can
23 turn the application on and off at will but will be instructed to keep it active for at least six
24 hours or while they sleep, every day for a minimum period of 30 days. In an adaptive design
25 aimed at improving retention, participants will have the possibility of extending their
26 participation to a 3-month and 6-month period.
27
28

29 249
30
31

32 250 Local epidemiology of respiratory disease 33

34 251 Digital medical data systems at the Zizur's health center and the Clínica Universidad de
35 Navarra will be reviewed monthly to establish the incidence of the following respiratory, or
36 cough-associated diseases in the participants cohort; COVID-19, influenza, respiratory
37 syncytial virus (RSV), pneumonia, asthma, bronchitis, pharyngitis, chronic cough, chronic
38 obstructive pulmonary disease (COPD), gastro-esophageal reflux disease (GERD), other
39 nonspecific respiratory tract infections. Specifically, for COVID-19, daily incidence figures for
40
41 255
42 256 nonspecific respiratory tract infections. Specifically, for COVID-19, daily incidence figures for
43
44

1
2
3 257 the study area (Cendea de Cizur, Zizur Mayor, and Pamplona), and regional population, will
4
5 258 also be obtained from local health authorities. Data will be aggregated and used to build local
6
7 259 epidemic curves of respiratory diseases during the study period.
8
9
10 260
11
12 261 **Barriers and facilitators to participation**
13
14 262 A participation cascade informing on the number of solicited, enrolled, and actively recording
15
16 263 participants will be tracked in real time throughout the study. The total number of user-hours
17
18 264 using Hyfe™ will also be monitored in real time.
19
20
21 265 All participants will be asked to fill a satisfaction survey in which they will be asked about the
22
23 266 usability of the app, the problems that they ran into, and their likelihood of using the app in
24
25 267 the future. We will follow-up with a group of 25 participants who are willing to attend a focus
26
27 268 group discussion (FGD) to better understand the barriers and facilitators affecting
28
29 269 participation in the cough-surveillance system. The 25 participants will include some of whom
30
31 270 deleted the application early on, who stopped using it after a month, and who had low
32
33 271 satisfaction scores.
34
35
36 272
37
38
39 273 **Patient and public involvement**
40
41 274 This study pilots an experimental syndromic surveillance approach at population level. The
42
43 275 municipal authorities of the Cendea de Cizur were informed about the nature of the study and
44
45 276 provided feedback on the best approach to recruit local participants. Similarly,
46
47 277 representatives of the University of Navarra's medical services collaborated on the design of
48
49 278 the study protocol including the review of recruitment strategies as well as data collection,
50
51 279 aggregation and reporting plans. No anticipated participants were involved in the study
52
53 280 design. Study findings are to be reported in both English and Spanish to participants and key
54
55 281 stakeholders at individual, municipality, and university levels during the surveillance phase.
56
57
58 282

1
2
3 283 **Data analysis and sample size calculations**
4
5 284 **Syndromic surveillance as a surrogate marker of respiratory disease activity**

6
7 285 Given the uncertainty around the incidence of the various respiratory diseases including
8
9 286 COVID-19, throughout the study period, it is impossible to establish a target sample size
10
11 287 sufficient to either confirm or confute with statistical significance that cough monitoring at
12
13 288 population level can predict incidence of respiratory diseases. We will endeavour to recruit
14
15 289 the highest number of participants possible in order to achieve the best representation of the
16
17 290 population.

18
19 291 First, cough data will be aggregated in time and space to create cough incidence curves and
20
21 292 geospatial heat maps reflecting the frequency and density of cough among the studied
22
23 293 population (Figure 3 and Figure 4). Second, epidemic curves reflecting the incidence of
24
25 294 targeted respiratory illnesses within the participants cohort, and the number of COVID-19
26
27 295 cases diagnosed in the study area and population will be generated with data collected from
28
29 296 the Clínica Universidad de Navarra, and Zizur's health center, as well as aggregated
30
31 297 epidemiological records obtained from regional health authorities, respectively. Coughs per
32
33 298 person-hour and clinical diagnoses data will be superposed in time. Finally, we will carry out
34
35 299 an autoregressive moving average (ARIMA) analysis to compare the incidence of confirmed
36
37 300 and forecasted respiratory diseases (including COVID-19) with the frequency of cough among
38
39 301 study participants, measured as coughs per person-hour. ARIMA analysis is a type of time
40
41 302 series analysis that uses past data to forecast the likely future behaviour of a variable. In brief,
42
43 303 the variable of interest is regressed to its own lagged values, and autoregression and partial
44
45 304 autocorrelation functions are used to model the stochastic nature of a time series. (11)
46
47 305 Comparison and prediction analyses will be performed using epidemic curves from both the
48
49 306 participants cohort and in the entire study area and population.
50
51 307
52
53 308 **Perceptions and willingness to participate in syndromic surveillance**

1
2
3 309 Mixed methods will be used to assess individual barriers and facilitators to participation in an
4 310 acoustic surveillance program. Among all eligible individuals in the Cendea de Cizur, Zizur
5 Mayor and in the University of Navarra who are invited to participate in the study, we will
6 311 assess how many do install the cough detection application and keep using it through the
7 312 course of the study. Participants corresponding to specific user profiles based on duration and
8 313 regularity of cough recording will be identified. We will then descriptively analyze the socio-
9 314 demographic characteristics, and baseline health conditions of participants belonging to the
10 315 different user profiles.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

317 A subsample of participants will be contacted once a month, by telephone or text messaging,
318 to obtain feedback from their experience using the app.

319 To assess population uptake of Hyfe™, as well as barriers and facilitators to participation, a
320 convenience subsample of 25 participants will be recruited for focus group discussions.
321 Following similar designs, FGDs will consist of two parts. (12) The first one will be aimed at
322 understanding a participant's awareness of their cough frequency and temporality patterns,
323 as well as the perceived importance of measuring these elements. Questions asked in this part
324 will include (i) How much attention do you pay to your coughs on a daily basis? (ii) How
325 important is it for you to know the number of times you cough per day? (iii) Will keeping track
326 of your coughs help you improve your health? The second one will focus on the participant's
327 experience using Hyfe™, as well as possible recommendations for developers to improve it.
328 This part will include the following general questions: (i) What do you like about the app, (ii)
329 What do you think of this app compared to other health apps, (iii) What doesn't work well,
330 (iv) What keeps you committed (or not) to using the app, (v) What do you think the purpose
331 of the app is, (vi) What advice do you have for the developers?

332
333 **Risks and privacy**

1
2
3 334 Recording sounds implies specific ethical and privacy concerns. These are, however,
4 335 addressable at different levels. First, sound snippets recorded are too short (<0.5 seconds) to
5 336 capture conversations or background sound. Participants can withdraw from the study at any
6 337 time, and the application can be turned off or removed from smartphones freely. Our consent
7 338 process explicitly describes exactly what is and what is not recorded. The use of pre-generated
8 339 unique identifiers to install and use the smartphone application ensures that only
9 340 investigators can link cough data to personal identifiers. Contact information collected from
10 341 participants will be kept in physical forms stored under lock, and password-protected files at
11 342 the University of Navarra. Only the principal investigator, study coordinator, and research
12 343 assistant will have access to this information. Data transferred to other researchers will only
13 344 include unique identifiers for individual participants, but no other personal information. All
14 345 acoustic data and metadata collected by the application is stored in encrypted servers
15 346 physically located in the United States. Data storage and access protocols are compliant with
16 347 General Data Protection Regulation (GDPR), and only non-identifiable data information is
17 348 stored by Hyfe.
18
19 349
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39 350 **Ethics and dissemination**
40
41 351 This study protocol was approved by the ethics committee of the Centre Hospitalier de
42
43 352 l'Université de Montréal, Canada (Reference numbers 2021-9247 20.253 & 2021-9270 20.226)
44
45 353 and the Medical Research Ethics Committee of Navarra, Spain (Reference number
46
47 354 PI107/2020). Any modifications to the approved protocol would be resubmitted to both
48
49 355 committees.
50
51
52 356 Preliminary summary results of this study will be regularly shared with participants via email
53
54 357 and through focal meetings. Final results will also be disseminated in open-access scientific
55
56
57 358 journals and international conferences. A two-page summary of results will be prepared in
58
59
60

1
2
3 359 Spanish and posted on the municipal and university website, and shared with local civil and
4
5 360 health authorities, as well as with individual participants.
6
7
8
9
10 361
11
12 362 **Discussion**
13
14 363 The current COVID-19 pandemic highlights the incapacity of existing surveillance networks to
15
16 364 rapidly curb the impact of emerging respiratory pathogens in the current globalized world.
17
18 365 (13) This is particularly true in low- and middle-income countries, where diagnostic and
19
20 366 contact-tracing efforts are limited by their crippling costs, and where epidemiological data
21
22 367 aggregation infrequently translates into actionable information because of delays inherent to
23
24 368 disaggregated and poorly digitalized health information systems. Continuous, individual-
25
26 369 based, and passive monitoring of cough among entire populations could represent
27
28 370 inexpensive large-scale surveillance networks contributing to the early detection of outbreaks
29
30 371 and enabling prioritized and focal delivery of limited resources.
31
32 372
33
34 373 AI and more specifically machine learning models, are increasingly used in disease surveillance
35
36 374 and can maximize the impact of limited available resources. (14) Integration of such models
37
38 375 with accurate digital epidemiological data was shown to provide reliable, near-real time
39
40 376 estimations of influenza disease incidence. (15) The widespread distribution of smartphones
41
42 377 coupled with the development of AI-enabled sound classification models now represent
43
44 378 another new potential breakthrough in public health and epidemic preparedness. Beyond
45
46 379 being able to detect cough, most smartphones have integrated geo-location functions. This
47
48 380 allows the integration of acoustic records with geo-spatial and temporal data and increases
49
50 381 the range of applications of acoustic surveillance systems for disease control. (16)
51
52 382
53
54 383 Apart from participating in a collective disease tracking and eradication effort, participants
55
56 384 monitoring their cough also benefit from objective feedback on their own symptomatology.
57
58
59
60

1
2
3 385 During a pandemic, such feedback could trigger appropriate healthcare seeking behaviours
4
5 386 and self-quarantine further helping to limit disease transmission at community level.
6
7 387
8
9

10 388 Implementing such an innovative approach to disease surveillance is contingent on
11
12 389 overcoming substantial challenges. Evidence suggests that users are typically willing to install
13
14 390 mobile apps with a clearly perceived health benefit. But this is often limited by issues such as
15
16 391 increased battery drainage, or disruption of daily activities by alerts and notifications. (17)
17
18 392 Specifically, for acoustic surveillance apps, protecting user's privacy must also be a priority, in
19
20 393 order to create the social trust needed to achieve a high uptake of these systems. To
21
22 394 guarantee this, users must be able to clearly understand the nature of these applications, as
23
24 395 well as to control their functioning at will. This means that the quality of the data recorded
25
26 396 will greatly depend on individual behaviours.
27
28
29 397
30
31

32 398 Despite proven technical capacity and tremendous potential in complementing surveillance
33
34 399 systems, whether listed challenges can be overcome and whether digital cough monitoring
35
36 400 can provide actionable public health information remains unknown. This study will address
37
38 401 those questions. It will also generate operational expertise and qualitative knowledge on the
39
40 402 facilitators to be exploited, and the barriers to be addressed in order to maximize uptake and
41
42 403 impact prior to implementation on a wider scale.
43
44
45 404
46
47
48
49 405 **Limitations and potential challenges**
50
51

52 406 Enrolment and retention are expected to represent the major limitations of this project.
53
54 407 Acoustic syndromic surveillance tools might be perceived as threatening for the privacy of
55
56 408 potential participants. Furthermore, the quantity of cough data recorded will heavily rely on
57
58 409 the regular use of the system by participants. The diversity of respiratory and non-respiratory
59
60

1
2
3 410 conditions that can cause cough, as well as the consumption of medications to treat them,
4
5 411 can make it difficult to link changes in cough frequency with epidemiological data. Finally,
6
7 412 asymptomatic, or mild infections of SARS-CoV-2 and other respiratory pathogens, mean that
8
9 413 a proportion of infected patients will not contribute to the cough-based surveillance system
10
11 414 and are unlikely to seek medical attention, reducing available cough and epidemiological data
12
13 415 necessary for the analysis. Those limitations and challenges reflect well the impediments to
14
15 416 larger scale deployment of cough-based syndromic surveillance for any respiratory disease
16
17 417 hence making this innovative study an ideal stress-test for such approach.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 **418 Acknowledgements**

3
4 **419** The authors want to thank the Municipality of the Cendea de Cizur, the University of Navarra
5
6 **420** and all participants for their trust and desire to participate in citizen science and altruistic
7
8 **421** population-level syndromic surveillance.

9
10 **422**

11 **423 Contributors**

12
13 **424** All authors meet criteria for authorship as per the BMJ Global Health policy and ICJME
14
15 **425** recommendations. Conceptualization (JCGF, JB, DD, NU, LYT, SGL, CCh), data curation (JCGF,
16
17 **426** JB, NU, CCh), formal analysis (JCGF, JB, NU, SGL, CCh), funding acquisition (SGL),
18
19 **427** investigation (JCGF, JCh, AFM, VO, IB, JBart, CCh), methodology (JCGF, JB, NU, SGL, CCh),
20
21 **428** supervision (JCGF, SGL, CCh), writing of the original draft (JCGF, CCh, SGL). All authors have
22
23 **429** read, reviewed, discussed, and approved the final manuscript and their respective
24
25 **430** representation in the authorship.

26
27 **431 Data sharing statement**

28
29 **432** Aggregated deidentified datasets will be available upon completion of the study by
30
31 **433** reasonable request to the corresponding author.

32
33 **434 Funding**

34
35 **435** This study was funded by the *Patrick J. McGovern Foundation* (grant name: "Early diagnosis of
36
37 **436** COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring"). The funders had no role
38
39 **437** in study design, data collection and interpretation, or the decision to submit the work for
40
41 **438** publication. CCh received salary support from Unitaid (grant name: BOHEMIA). ISGlobal
42
43 **439** acknowledges support from the Spanish Ministry of Science and Innovation through the
44
45 **440** "Centro de Excelencia Severo Ochoa 2019-2023" Program (grant number: CEX2018-000806-
46
47 **441** S), and support from the Generalitat de Catalunya through the CERCA program.
48
49 **442**

443 **Competing interest**

444 JB is the CEO of Hyfe™ Inc. Hyfe Inc had no role in the decision to submit this protocol for
445 publication. All other authors declare no competing interests. Upon submission of this
446 protocol for publication, JCG, SGL and CCh had full access to all the data available and assumed
447 responsibility for the decision to submit the manuscript content for publication.

448

449 **References**

450 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
451 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.

452 2. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic
453 and symptomatic patients with mild COVID-19. *Clin Microbiol Infect*. 2020;26(7):948.e1-e3.
454 PubMed PMID: 32360780. Epub 05/01. eng.

455 3. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The
456 prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2;
457 COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. *PLoS One*.
458 2020;15(6):e0234765-e. PubMed PMID: 32574165. eng.

459 4. Agrawal A, Bhardwaj R. Probability of COVID-19 infection by cough of a normal person and
460 a super-spreader. *Physics of Fluids*. 2021 2021/03/01;33(3):031704.

461 5. Hall JL, Lozano M, Estrada-Petrocelli L, Birring S, Turner R. The present and future of cough
462 counting tools. *J Thorac Dis*. 2020;12(9):5207-23. PubMed PMID: 33145097. eng.

463 6. Rasheed J, Jamil A, Hameed AA, Aftab U, Aftab J, Shah SA, et al. A survey on artificial
464 intelligence approaches in supporting frontline workers and decision makers for the COVID-
465 19 pandemic. *Chaos, Solitons, and Fractals*. 2020;141:110337 -

466 7. Kvapilova L, Boza V, Dubec P, Majernik M, Bogar J, Jamison J, et al. Continuous Sound
467 Collection Using Smartphones and Machine Learning to Measure Cough. *Digit Biomark*.
468 2019;3(3):166-75. PubMed PMID: 32095775. eng.

- 1
2
3 469 8. Peeling RW, Wedderburn CJ, Garcia PJ, Boeras D, Fongwen N, Nkengasong J, et al. Serology
4 470 testing in the COVID-19 pandemic response. *The Lancet Infectious Diseases.* 2020
5 471 2020/09/01;20(9):e245-e9.
6
7 472 9. Chowdhury R, Luhar S, Khan N, Choudhury SR, Matin I, Franco OH. Long-term strategies to
8 473 control COVID-19 in low and middle-income countries: an options overview of community-
9 474 based, non-pharmacological interventions. *European Journal of Epidemiology.* 2020
10 475 2020/08/01;35(8):743-8.
11
12 476 10. Farkas K, Hillary LS, Malham SK, McDonald JE, Jones DL. Wastewater and public health:
13 477 the potential of wastewater surveillance for monitoring COVID-19. *Curr Opin Environ Sci
14 478 Health.* 2020;17:14-20. PubMed PMID: 32835157. Epub 06/12. eng.
15
16 479 11. Ho SL, Xie M. The use of ARIMA models for reliability forecasting and analysis. *Computers
17 480 & Industrial Engineering.* 1998 1998/10/01/;35(1):213-6.
18
19 481 12. Nouvet E, Knoblauch AM, Passe I, Andriamiadanarivo A, Ravelona M, Ainanomena
20 482 Ramtariharisoa F, et al. Perceptions of drones, digital adherence monitoring technologies and
21 483 educational videos for tuberculosis control in remote Madagascar: a mixed-method study
22 484 protocol. *BMJ Open.* 2019;9(5):e028073.
23
24 485 13. WHO Coronavirus (COVID-19) Dashboard: World Health Organization; 2021 [cited 2021
25 486 06/03]. Available from: <https://covid19.who.int/>.
26
27 487 14. Naseem M, Akhund R, Arshad H, Ibrahim MT. Exploring the Potential of Artificial
28 488 Intelligence and Machine Learning to Combat COVID-19 and Existing Opportunities for LMIC:
29 489 A Scoping Review. *Journal of Primary Care & Community Health.* 2020
30 490 2020/01/01;11:2150132720963634.
31
32 491 15. Santillana M, Nguyen AT, Louie T, Zink A, Gray J, Sung I, et al. Cloud-based Electronic Health
33 492 Records for Real-time, Region-specific Influenza Surveillance. *Scientific Reports.* 2016
34 493 2016/05/11;6(1):25732.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 494 16. Mukundarajan H, Hol FJH, Castillo EA, Newby C, Prakash M. Using mobile phones as
4 495 acoustic sensors for high-throughput mosquito surveillance. eLife. 2017
5 496 2017/10/31;6:e27854.
6
7
8 497 17. Liss DT, Serrano E, Wakeman J, Nowicki C, Buchanan DR, Cesan A, et al. "The Doctor Needs
9 498 to Know": Acceptability of Smartphone Location Tracking for Care Coordination. JMIR mHealth
10 499 and uHealth. 2018 May 4;6(5):e112. PubMed PMID: 29728349. Pubmed Central PMCID:
11 500 PMC5960037. Epub 2018/05/08. eng.
12
13
14
15
16
17
18
19 501
20 502 **Supplementary materials**
21
22 503 1. Informed Consent Form
23
24 504 2. Assent form
25
26 505 3. Complementary medical questionnaire for participants
27
28 506 4. SPIRIT Checklist
29
30
31
32 507 I, the Submitting Author has the right to grant and does grant on behalf of all authors of the
33
34 508 Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive
35
36 509 licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has
37
38 510 agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US
39
40 511 Federal Government officers or employees acting as part of their official duties; on a
41
42 512 worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its
43
44 513 licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the
45
46 514 Journal, to publish the Work in BMJ Global Health and any other BMJ products and to exploit
47
48 515 all rights, as set out in our [licence](#).
49
50
51
52 516
53
54 517 The Submitting Author accepts and understands that any supply made under these terms is
55
56 518 made by BMJ to the Submitting Author unless you are acting as an employee on behalf of
57
58 519 your employer or a postgraduate student of an affiliated institution which is paying any
59
60

1
2
3 520 applicable article publishing charge ("APC") for Open Access articles. Where the Submitting
4
5 521 Author wishes to make the Work available on an Open Access basis (and intends to pay the
6
7 522 relevant APC), the terms of reuse of such Open Access shall be governed by a Creative
8
9 523 Commons licence – details of these licences and which [Creative Commons](#) licence will apply
10
11 524 to this Work are set out in our licence referred to above.
12
13
14
15 525 **Figure legends**
16
17
18 526 **Figure 1:** Study design, timeline and monitoring plan for the study's primary objective.
19
20
21 527 **Figure 2:** Receiver operating characteristic (ROC) analysis showing an area under the curve
22 528 (AUC) of 0.995 for the classification of cough in participants recruited between November
23 529 and December 2020.
24
25 530 **Figure 3:** Coughs per person-hour registered in participants recruited between November
26 531 2020 and January 2021.
27
28
29 532 **Figure 4:** Heatmap of registered cough episodes in the municipalities of Zizur Mayor, Cendea
30 533 de Cizur, and Pamplona between November 2020 and March 2021 (The Cendea de Cizur is
31 534 an incontiguous municipality).




Figure 1

230x128mm (96 x 96 DPI)




Figure 2

147x79mm (96 x 96 DPI)




Figure 3

115x99mm (96 x 96 DPI)




Figure 4

157x151mm (96 x 96 DPI)



1

2

3

4

5

HOJA DE INFORMACIÓN Y CONSENTIMIENTO

6

7

8

Versión 3.0, 6 de enero de 2021

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

HOJA DE INFORMACIÓN Y CONSENTIMIENTO

Versión 3.0, 6 de enero de 2021

TÍTULO DEL ESTUDIO: Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.

CÓDIGO DEL PROMOTOR:

PROMOTOR

Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona.

FINANCIACIÓN:

Este estudio está siendo financiado por el Centre Hospitalier de l'Université de Montréal (CHUM) y la fundación Patrick J. McGovern a través de una subvención otorgada al co-investigador Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*).

INVESTIGADOR PRINCIPAL

Carlos Chaccour

Teléfono +34 666 293 112

Email cchaccour@unav.es

INTRODUCCIÓN

Nos dirigimos a usted para informarle sobre un estudio de investigación en el que se le invita a participar. El estudio ha sido aprobado por un Comité de Ética de la Investigación de la Universidad de Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité de ética del Centre Hospitalier de l'Universite de Montréal (CHUM), en Canadá.

Con este documento pretendemos que usted reciba la información adecuada para que pueda entender de qué se trata el estudio y decidir si desea o no participar en el mismo. Para ello, lea esta hoja informativa con atención y nosotros le aclararemos las dudas que puedan surgir después de la explicación. Además, puede consultar con las personas que considere oportuno.

PARTICIPACIÓN VOLUNTARIA



Debe saber que su participación en este estudio es voluntaria y que puede decidir no participar o cambiar su decisión y retirar el consentimiento en cualquier momento, sin que por ello se altere la relación con su médico ni se produzca perjuicio alguno en su tratamiento.

DESCRIPCIÓN GENERAL DEL ESTUDIO

Los coronavirus son un grupo de virus que causan infecciones respiratorias generalmente leves. Sin embargo, un miembro de este grupo, el SARS-CoV-2, es el responsable de provocar la COVID-19, una enfermedad potencialmente peligrosa que desde finales del 2019 se ha extendido a lo largo de todo el mundo.

Uno de los elementos necesarios para contener el avance de la pandemia de COVID-19 es entender su escala real. Esto es particularmente importante ahora que los brotes regulares en zonas en las que simultáneamente ocurre transmisión a una menor escala se han convertido en una realidad. Uno de los mayores obstáculos de los sistemas sanitarios es la limitada capacidad de hacer pruebas diagnósticas, lo que se traduce en retrasos en la búsqueda de atención médica, así como en la recolección de la información necesaria para planear intervenciones que limiten la expansión de la enfermedad.

La gran mayoría de pacientes con COVID-19 presentan tos como un síntoma temprano de la enfermedad. Este estudio pretende evaluar la utilidad de una aplicación para el móvil, llamada HyfeApp, que registra y evalúa patrones de tos, como complemento a las estrategias de vigilancia epidemiológica existentes. Para esto, estimamos que será necesario grabar y analizar episodios individuales de tos.

Por eso esperamos que el mayor número posible de habitantes instale la aplicación. Esta aplicación se ejecuta en segundo plano en el móvil. Aunque HyfeApp tiene acceso continuo al micrófono de su móvil, ha sido diseñada para procesar únicamente sonidos compatibles con las características de la tos humana. Cuando uno de estos sonidos es detectado y grabado por la aplicación, un algoritmo de inteligencia artificial lo estudia y en caso de decidir qué se trata de un episodio de tos, se guarda junto a la información sobre la ubicación geográfica y el momento en que ocurrió, que es proporcionada por el sistema GPS del móvil.

Aparte de la información suministrada por la aplicación, también revisaremos los registros médicos de aquellas personas dispuestas a participar que acudan a consulta en el sistema nacional de salud, o la Clínica Universidad de Navarra. El objetivo de esto es recolectar información sobre la presencia de tos durante la exploración médica, o el diagnóstico de alguna enfermedad respiratoria en alguna de las visitas. Solo se consultará información relacionada con alguna de las siguientes condiciones:

- TOS NO ESPECÍFICA.
- INFECCIONES DEL TRACTO RESPIRATORIO SUPERIOR.
- FARINGITIS.
- ASMA.
- BRONQUITIS.
- ENFERMEDAD BRONCOPULMONAR OBSTRUCTIVA CRÓNICA (EBPOC).
- COVID-19



- Enfermedad por Reflujo Gastroesofágico (ERGE)
- Influenza
- Neumonía (por cualquier causa)
- Infección por virus sincitial respiratorio (VSR)
- Infecciones respiratorias inespecíficas.

Otros exámenes paraclínicos a ser recolectados incluyen:

- Microbiología
 - Pruebas de COVID-19
 - PCR para influenza
 - Cultivo de esputo
- Hematología
 - Hematología completa
 - Prueba del dímero D.
- Bioquímica
 - Proteína C reactiva
 - Procalcitonina
 - CPK
 - LDH
 - Ferritina

Aparte de la información obtenida de la app y sus registros médicos, también le pediremos a un grupo reducido de participantes que formen parte de discusiones grupales focalizadas, para explorar los desafíos que representa el uso continuo de HyfeApp, y su participación en el estudio. En caso de que se le solicite participar, usted podrá aceptar o negarse.

Duración

Se recolectará información inicialmente por un período de 1 mes, consultándosele en ese momento su disposición a seguir participando por 3 y 6 meses. Usted podrá negarse a seguir participando en el estudio en cualquier momento.

Procedimientos del estudio

Usted no puede participar en el ensayo si:

- No puede o no quiere aceptar compartir su información codificada, relacionada a sus registros de tos con bases de datos usadas para refinar los diagnósticos basados en perfiles acústicos.
- Si tiene menos de 13 años de edad.
- Si no tiene un teléfono inteligente capaz de ejecutar HyfeApp.
- Si no es un estudiante/trabajador de la Universidad de Navarra, o un paciente diagnosticado con una enfermedad causante de tos en la Clínica Universidad de Navarra.



- 1
2
3 • Si no es residente en Navarra.
4
5
6
7
8
9
10
11
12
13

Si usted decide participar, un miembro de nuestro equipo lo ayudará a instalar la aplicación en su móvil. No serán necesarias nuevas visitas de parte del equipo de investigación, pero serán contactados una vez al mes para obtener comentarios sobre su experiencia usando la aplicación y ratificar su consentimiento y disposición a seguir participando en el estudio. También podrá ser contactado vía correo electrónico para recibir actualizaciones periódicas sobre el estado del proyecto y sus resultados preliminares.

14 15 **LA APLICACIÓN HYFEAPP** 16

17 HyfeApp es una aplicación móvil disponible para los sistemas operativos Android y iOS (Apple),
18 desarrollada por un equipo multidisciplinario que incluye analistas de datos, desarrolladores de
19 software y médicos especialistas en enfermedades infecciosas.
20
21
22

23 **¿Qué hace HyfeApp?**

24 HyfeApp se ejecuta constantemente en el segundo plano de su móvil, sin interferir con el
25 funcionamiento de otras aplicaciones, pero teniendo acceso a su micrófono y grabando recortes de
26 sonidos explosivos de menos de 0.5 segundos de duración. Ni las conversaciones, ni los sonidos de
27 fondo son grabados. Estos recortes son enviados a un servidor, donde un algoritmo de inteligencia
28 artificial identifica aquellos que presentan cambios súbitos y cortos en los decibeles, compatibles con
29 episodios de tos. Posteriormente, otro algoritmo los procesa, evaluando otras características y
30 determinando si efectivamente se trató de un episodio de tos. El servidor envía esta información de
31 vuelta al móvil, de forma que los archivos clasificados como tos se incorporan a los registros mostrados
32 por la aplicación.
33
34

35 HyfeApp es una herramienta que le proporciona información sobre su estado de bienestar. Tal como
36 herramientas similares que cuentan calorías, registran el número de pasos o ronquidos. La única
37 diferencia es que HyfeApp cuenta episodios de tos.
38
39

40 41 **42 Beneficios y riesgos por su participación en estudio** 43

44 HyfeApp le permitirá llevar un registro del número de veces que tose al día, así como evidenciar
45 cambios con respecto a días anteriores. Sin embargo, no es una herramienta de diagnóstico o
46 tratamiento médico. Por lo tanto, ni provee información o consejos médicos, ni sustituye de ninguna
47 forma a los servicios sanitarios: HyfeApp no es un instrumento médico especializado. Si usted tiene
48 alguna duda sobre su estado de salud, debe consultarlas con un médico o en caso de emergencia,
49 llamar a los servicios respectivos inmediatamente .
50
51

52 Grabar sonidos desde un móvil inmediatamente genera dudas sobre la forma en que será manejada
53 la información, y garantizada la privacidad de los participantes. Como hemos explicado anteriormente,
54 HyfeApp no graba conversaciones ni sonidos de ambiente. Los segmentos de 0.5 segundos grabados
55 por la aplicación no permiten identificar a los participantes. Sin embargo, algunos de estos sonidos
56 pudiesen permitir identificar al participante si son interpretados en conjunto a otra metadata
57 registrada por la aplicación (como el número de teléfono, por ejemplo). Por esta razón, toda la
58
59
60



información transmitida por la aplicación estará encriptada y manejada según los protocolos de seguridad estándar empleados en este tipo de estudios. De esta forma, únicamente los investigadores podrán asociar los datos recolectados por la aplicación, a otros elementos que permitan identificar a los participantes.

No será remunerado por su participación en este estudio.

CONFIDENCIALIDAD

Toda la información recolectada en este estudio se mantendrá codificada, de forma que no pueda ser vinculada a sus datos personales. Solo el investigador principal y los co-investigadores sabrán su nombre y en cualquier documento o comunicación se usará un número de identificación personal asignado a cada participante. Los ordenadores utilizados para analizar los datos de este estudio tendrán contraseñas y solo investigadores autorizados podrán acceder a ellas.

La Universidad de Navarra, como responsable del tratamiento de datos, se compromete al cumplimiento de la Ley Orgánica del 3/2018, de 5 de diciembre y demás normativa de protección de datos en vigor. Por ello, es importante que conozca la siguiente información:

- Además de los derechos que ya conoce (acceso, modificación, oposición y cancelación de datos) ahora también puede limitar el tratamiento de datos que sean incorrectos, solicitar una copia o que se trasladen a un tercero (portabilidad) los datos que usted ha facilitado para el estudio. Para ejercer sus derechos, diríjase al Delegado de Protección de Datos de la institución en [\[protecciondedatosnav@unav.es\]](mailto:[protecciondedatosnav@unav.es]). Así mismo tiene derecho a dirigirse a la Agencia de Protección de Datos si no quedara satisfecho/a.

- Tanto el Centro como el Promotor son responsables respectivamente del tratamiento de sus datos y se comprometen a cumplir con la normativa de protección de datos en vigor. Los datos recogidos para el estudio estarán identificados mediante un código, de manera que no se incluya información que pueda identificarle, y sólo su médico del estudio/colaboradores podrá relacionar dichos datos con usted y con su historia clínica. Por lo tanto, su identidad no será revelada a ninguna otra persona salvo a las autoridades sanitarias, cuando así lo requieran o en casos de urgencia médica. Los Comités de Ética de la Investigación, los representantes de la Autoridad Sanitaria en materia de inspección y el personal autorizado por el Promotor, únicamente podrán acceder para comprobar los datos personales, los procedimientos del estudio clínico y el cumplimiento de las normas de buena práctica clínica (siempre manteniendo la confidencialidad de la información).

- El Investigador y el Promotor están obligados a conservar los datos recogidos para el estudio al menos hasta 25 años tras su finalización. Posteriormente, su información personal solo se conservará por el centro para el cuidado de su salud y por el promotor para otros fines de investigación científica si usted hubiera otorgado su consentimiento para ello, y si así lo permite la ley y requisitos éticos aplicables.

- Si realizáramos transferencia de sus datos codificados fuera de la UE a las entidades de nuestro grupo, a prestadores de servicios o a investigadores científicos que colaboren con nosotros, los datos del participante quedarán protegidos con salvaguardas tales como contratos u otros mecanismos por las autoridades de protección de datos. Si el participante quiere saber más al respecto, puede contactar al Delegado de Protección de Datos del promotor [\[protecciondedatosnav@unav.es\]](mailto:[protecciondedatosnav@unav.es]).



COMPENSACIÓN ECONÓMICA

El promotor del estudio es el responsable de gestionar la financiación del mismo. Para la realización del estudio, el promotor ha firmado un contrato con el centro donde se va a realizar y con el médico del estudio.

Su participación en este estudio no le causará costes adicionales diferentes de los asociados a su tratamiento habitual. La asistencia rutinaria deberá ser pagada por la seguridad social, por su seguro médico o por usted mismo.

Usted no recibirá ninguna compensación económica por su participación en este estudio.

OTRA INFORMACIÓN RELEVANTE

Cualquier nueva información referente a la aplicación utilizada en el estudio y que pueda afectar su disposición para participar en el mismo, que se descubra durante su participación, le será comunicada lo antes posible.

Si usted decide retirar el consentimiento para participar en este estudio, no se añadirán nuevos datos a la base de datos y puede exigir la destrucción de cualquier información identificable previamente retenidas para evitar la realización de nuevos análisis.

También debe saber que puede ser excluido del estudio si el promotor y/o los investigadores del estudio lo consideran oportuno, ya sea por motivos de seguridad, por cualquier acontecimiento adverso derivado de su participación, o porque consideren que no está cumpliendo con los procedimientos establecidos. En cualquiera de los casos, usted recibirá una explicación adecuada del motivo que ha ocasionado su retirada del estudio.

COMPARTIENDO LOS RESULTADOS

Usted tendrá acceso a todo el conocimiento generado por esta investigación en todo momento, solo debe preguntar al investigador principal. No compartiremos su nombre, estado de salud o dirección. Eventualmente, los resultados serán publicados, de forma tal que cualquier persona interesada en conocerlos, pueda acceder a ellos. Usted podrá solicitar información sobre el estado y los resultados del estudio, preguntándole directamente al investigador principal.

Al firmar el formulario de consentimiento adjunto, se compromete a cumplir con los procedimientos del estudio que se le han expuesto.

DERECHO A NEGARSE A PARTICIPAR O ABANDONAR EL ESTUDIO

- No tiene que participar en este estudio si no desea hacerlo.
- Tiene el derecho a NO firmar este formulario. Si no desea firmar este formulario, no podrá participar en este estudio de investigación. Esto se debe a que necesitamos su permiso por escrito antes de poder usar su información.
- Tiene el derecho a abandonar este estudio incluso después de haber aceptado participar. Si decide abandonar el estudio, no usaremos su información. En caso de decidir



abandonar el estudio, por favor comuníquese con un miembro de nuestro personal. No tiene que explicar sus razones para abandonar el estudio.

A QUIÉN CONTACTAR

Si no está satisfecho con la forma en que se llevó a cabo este estudio, o tiene alguna duda, queja o pregunta sobre sus derechos como participante, por favor contacte a la oficina de atención al paciente de la Clínica Universidad de Navarra, por teléfono (+34 948 255 400) o correo electrónico (atpatientun@unav.es), para hablar con alguien independiente del equipo investigador.

Si tiene alguna duda sobre este estudio o sus procedimientos, ahora o en el futuro, puede comunicarse con: _____ . Teléfono: _____. Quién es el investigador principal del estudio. Puede llamar de lunes a viernes entre las 8:00 y las 17:00 horas.

Al firmar el formulario de consentimiento adjunto, se compromete a cumplir con los procedimientos del estudio que se le han expuesto.

Consentimiento Informado por escrito

TÍTULO DEL ESTUDIO: Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.

CÓDIGO DEL PROMOTOR:

Versión y fecha:

Yo, (nombre y apellidos)

He leído la hoja de información que se me ha entregado.

He podido hacer preguntas sobre el estudio.

He recibido suficiente información sobre el estudio.

He hablado con:

(nombre y dos apellidos del investigador)

Comprendo que mi participación es voluntaria.

Comprendo que puedo retirarme del estudio:

1º Cuando quiera



2º Sin tener que dar explicaciones.

3º Sin que esto repercuta en mis cuidados médicos.

Presto libremente mi conformidad para participar en el estudio y doy mi consentimiento para el acceso y utilización de mis datos en las condiciones detalladas en la hoja de información

Firma del investigador:

Nombre:

Fecha:

Firma del investigador:

Firma del participante:

Firma del Representante legal o Testigo imparcial (tácheselo lo que no proceda):

Nombre:

Nombre:

DNI:

Fecha:

Fecha:

Fecha:

A causa de:

Este documento se firmará por duplicado quedándose una copia el investigador y otra el participante.

**INFORMATION AND CONSENT SHEET****Version 3.0 (January 6th, 2021)**

Study Title: Acoustic surveillance and digital cough monitoring at population level for early respiratory disease outbreak detection, an exploratory observational study

Promoter Code:

Promoter

Clinica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona

Funder: This study is funded by the Centre Hospitalier de l'Université de Montréal (CHUM) and the Patrick J. McGovern Foundation through a grant awarded to Co-Investigator Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*)

Main Researcher:

Carlos Chaccour
Teléfono +34 666 293 112
Email cchaccour@unav.es

Introduction

The objective of this document is to inform you about the characteristics of a research study you have been invited to participate in. The study has been approved by the Committee of Research Ethics of the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the ethics committee from the Centre Hospitalier de l'Université de Montréal (CHUM), in Canada.

This document aims to provide you with proper information, so you can understand this study and decide by yourself if you are willing to take part or not in it. Please read this information document carefully and we will answer any questions that might come up afterwards. You can also discuss this with people you trust before making a decision.

Voluntary Participation

You must know that your participation in this study is voluntary and you can decide not to take part, or change your mind and withdraw your consent at any time in the future. This will not affect your relationship with your healthcare provider, nor harm your access to proper medical treatment in any way.

General description of the study

Coronaviruses are a group of viruses that cause generally mild respiratory disease. However, a member of this group, the SARS-CoV-2, is responsible for causing COVID-19, a potentially dangerous disease that has spread across the globe since 2019.

One of the necessary interventions to contain the COVID-19 pandemic is understanding its real scale. This is particularly important now that new outbreaks are being regularly reported in areas with ongoing low-level transmission. A major limitation in this process is the limited diagnostic capabilities of many countries, which translates into delays in the search of medical attention and collection of necessary epidemiological data.



Most patients with COVID-19 present cough as an early symptom of disease. This study aims to evaluate the usefulness of a mobile app called HyfeApp, which registers and studies cough patterns, as a complement to existing disease surveillance strategies. To do this, we will need to record and analyse episodes of cough in the town of Cizur Menor which has been selected as the location of the initial studies of this new platform.

For this reason, we need as many people as possible installing the app. This App runs in the background of your mobile phone. Although HyfeApp has continuous access to the mobile's mic, it has been designed to exclusively process sounds that match the characteristics of human cough. When one of these sounds is detected and recorded by the app, an artificial intelligence algorithm studies it and determines whether it is indeed an episode of cough. If so, the record is stored, along with time and geographical information provided by the mobile's GPS.

Besides the information from the app, we will also review the medical records of those participants who present for a medical consultation in the national health system or the Clinica Universidad de Navarra. The objective of this is to collect information about the presence of cough, or any respiratory disease during one of those visits. Data from your medical chart will be obtained by the investigators from your local clinic or hospital. This includes without being limited to information related to any of the following conditions will be reviewed:

- Non-specific cough
- Non-specific upper respiratory tract infections
- Pharyngitis
- Asthma
- Bronchitis
- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19
- Gastro-esophageal reflux disease (GERD)
- Influenza
- Pneumonia (any cause)
- Respiratory Syncytial virus
- Non-specific respiratory tract infections

Additional laboratory test data to be collected from the selected visits includes:

- Microbiology
 - COVID-19 tests
 - Flu PCR
 - Sputum culture
- Hematology
 - Full blood count
 - D-dimer test
- Biochemistry
 - C-reactive protein
 - Procalcitonin
 - CPK
 - LDH
 - Ferritin
- Radiology



- 3 ○ Chest X-Ray
- 4 ○ Thorax CT-Scan

5
6 Besides the information from the app and medical charts, we will also solicit a restricted number of
7 participants to participate in focus group discussions to explore the challenges related to using
8 HyfeApp and participating in this study. If solicited, it will be your right to accept or refuse to
9 participate in those focus groups.

10 **Duration**

11 Data will be initially collected for a one-month period. You will then be offered the opportunity to
12 continue in the study for 3 and 6 months. You can refuse continuing in the study at any point.

13 **Study Procedures**

14 You will not be able to enroll in this study if you:

- 15 ● Are incapable or unwilling to accept to share your codified cough data with multicenter
16 databases aiming at refining acoustic-based diagnostics.
- 17 ● Are under 13 years of age.
- 18 ● Do not own a smartphone able to run HyfeApp.
- 19 ● Are not a student/worker at the University of Navarra or a patient diagnosed with cough-
20 related disease at the Clínica Universidad de Navarra.
- 21 ● Are not a resident in Navarra.

22 In case you decide to take part, a member of our team will help you install the app on your mobile.
23 No further visits from the research team will be necessary, but you might be contacted once a
24 month to collect feedback on your experience using the app, as well as to confirm your willingness to
25 continue in the study. You might also receive periodic updates via email, to keep you informed on
26 the status of the project and relevant preliminary results.

27 **About HyfeApp**

28 HyfeApp is a mobile app available for Android and IOS (Apple) operating systems, developed by a
29 multidisciplinary team of data scientists, software developers and infectious disease physicians.

30 **What does HyfeApp do?**

31 HyfeApp runs in the background of your mobile, without interfering with any other running app, but
32 having constant access to your mic and recording explosive sound snips of 0.5 seconds or less. No
33 conversations, nor ambient sounds are recorded. These sound snips are sent to a server, where an
34 artificial intelligence algorithm processes them, evaluating their characteristics and determining if
35 they were in fact, cough. The server then sends that data back to the mobile and the study investigator,
36 so those files labeled as cough episodes are displayed by the app. HyfeApp is a wellness status tool.
37 Just like similar apps that count calories, steps or snores. HyfeApp simply counts episodes of cough.

38 **Benefits and risks of participating**

39 HyfeApp will allow you to have a record of the number of times you cough every day, and of any
40 changes compared to previous days. However, it is not a diagnostic or treatment tool. Therefore, it
41 does not provide medical advice, nor replaces healthcare services. HyfeApp is not medical equipment.
42 If you ever have doubts regarding your health condition or status, you should consult a doctor, or in
43 case of emergency, communicate with proper emergency services.

44 We are aware that recording sounds from a mobile phone generates doubts regarding the handling
45 of information and the participants' privacy. As explained before, HyfeApp does not record
46 conversations or ambient sounds, and the 0.5 second sound snips are too short to identify



participants. However, if linked to other metadata (such as telephone numbers), these sounds could allow identification. For this reason, all the information transmitted by the app is encrypted and handled following standard safety protocols. This way, we can make sure that only the researchers can access potentially identifiable data.

You will not be paid for your participation.

Confidentiality

All the information collected in this study will be codified in such a way that it cannot be linked to your personal data. Only the principal and co-investigators involved in this study will know your name, and an ID number will be used to refer to you in every document or communication. The computers used to store and analyze the data will be password-protected and only authorised researchers will have access to them.

The Universidad de Navarra, as the data controller, complies with the Organic Law 3/2018, of December 5, and other Spanish data protection regulations in force. Therefore, it is important that you know the following information:

- In addition to the rights that you already know (access, modification, refusal and cancellation of data), you can now also limit the processing of incorrect data, request a copy, or have the data that you provided be transferred to a third party (portability) for the study. To exercise your rights, contact the Institution's Data Protection Officer at [protecciondedatosnav@unav.es]. You also have the right to contact the Data Protection Agency if you are not satisfied.
- Both the Center and the Promoter are respectively responsible for the processing of your data and undertake to comply with the data protection regulations in force. The data collected for the study will be identified by a code, so that information that can identify you is not included, and only your study doctor / collaborators will be able to relate said data to you and to your medical history. Therefore, your identity will not be revealed to any other person except to the health authorities, when required or in cases of medical emergency. The Research Ethics Committees, the representatives of the Health Authority in matters of inspection and the personnel authorized by the Sponsor, may only access to verify personal data, clinical study procedures and compliance with the rules of good clinical practice (always maintaining the confidentiality of the information).
- The Researcher and the Sponsor are obliged to keep the data collected for the study for at least 25 years after its completion. Subsequently, your personal information will only be kept by the center for the care of your health and by the promoter for other scientific research purposes if you have given your consent to do so, and if this is allowed by the law and applicable ethical requirements.
- If we transfer your encrypted data outside the EU to our group entities, service providers or scientific researchers who collaborate with us, the participant's data will be protected with safeguards such as contracts or other mechanisms by the protection authorities of data. If the participant wants to know more about it, he or she can contact the promoter's Data Protection Officer [protecciondedatosnav@unav.es].

Economic Compensation

The study promoter is responsible for managing the funds. Before doing a research study, the promoter must have signed a contract with the center where the study will take place, and the doctors



3 who will conduct the study. Your participation in this study will not cost you any
4 extra money beyond your standard medical procedures. Routine medical assistance will have to be
5 paid by the social security network, your medical insurance, or yourself.
6

7 You will not receive any payment or monetary compensation for taking part in this study.
8

9
10 **Other relevant information**

11 Any new information regarding the app to be used in this study and that could affect your disposition
12 to take part in it, discovered after you have decided to participate, will be communicated to you as
13 soon as possible.
14

15 If you wish to withdraw your consent to take part in the study, no further personal data will be added
16 to the database. You can also demand the destruction of any previously retained identifiable
17 information, to prevent new analysis from being carried on.
18

19 You must also know that you could be excluded from the study if the promoter and/or researchers
20 consider it to be adequate, either for your own safety, to prevent any adverse consequence deriving
21 from your participation, or because they consider you are not complying with the established
22 procedures. In any case, you will always receive a proper explanation of what caused your withdrawal
23 from the study.
24

25 **Sharing the results**

26 At all time, you will have access to the knowledge we get from the research upon request to the
27 principal investigator. We will not share your name, health status or where you live. After this, we will
28 publish the results so that other interested people may learn from our research. You will be able to
29 ask the status of this study and its findings by a direct request to the principal investigator.
30

31 **Right to refuse or withdraw**

32 You don't have to take part in this research study if you do not wish so. You have the right not to sign
33 this form. If you do not sign this form, you cannot take part in this research study. This is because we
34 need your written permission to use your information. You have the right to leave the research study.
35 If you would like to leave the research study, please tell a member of the study staff. You do not need
36 to explain why you want to leave.
37

38 **Who to contact?**

39 If you are not satisfied with the way this study was conducted, or if you have any concerns,
40 complaints or general questions about your rights as a participant, please contact the Patient
41 Attention Office at the Clínica Universidad de Navarra by phone (+34 948 255 400) or email
42 atpacientun@unav.es to talk with someone independent of the research team.
43

44 If you have any questions about this study or study procedures now or in the future, you can call Dr.
45 Carlos Chaccour. Tel number: 628 659 003 who is the Principal Investigator of the study. You can call
46 Monday-Friday from 8.00 to 17.00 hrs.
47

48 By signing the following informed consent, you agree to comply with the previously explained study
49 procedures.
50



Written informed consent form

Study title: Acoustic surveillance and digital cough monitoring at population level for early respiratory disease outbreak detection, an exploratory observational study

Promoter code

Version and date:

I, (name and surname)

Have read the information sheet presented above.

I have been allowed to ask questions about the study.

I have received sufficient information about the study to make a decision.

I have spoken to:

(Name and surname of researcher)

I understand that my participation is voluntary.

I understand I can withdraw from the study:

1. Whenever I want to.
2. Without having to explain my reasons.
3. Without repercussions regarding my access to healthcare.

I freely and willingly accept to participate in this study. I give my consent for the access and usage of my data within the conditions previously detailed in the information sheet.

Researcher's signature

Name:

Date:

Researcher's signature

Participant's signature

Signature of the legal representative or impartial witness (cross out if not applicable)

Name:

Name::

DNI:



1 Date:

2 Date::

3 Date:

4 Reason to sign:

5 This document will be signed in duplicate, one copy will be kept by the researcher and another one by
6 the participant.

For peer review only



1
2
3
4 ID del participante:
5
6
7
8
9

10 **Hoja de información y autorización a menores de entre 13 y 18 años para participar en el estudio**
11 **titulado:**
12
13

14 **Version 3.0 (6 de enero de 2021)**
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Vigilancia acústica y monitorización digital de la tos a nivel poblacional para la detección temprana
de brotes de enfermedades respiratorias. Un estudio observacional exploratorio.*

Este formulario de autorización es para aquellos menores de edad dispuestos a participar en el estudio observacional previamente descrito.

Promotor

Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31008 Pamplona.

Financiación: Este estudio está siendo financiado por el Centre Hospitalier de l'Université de Montreal (CHUM) y la fundación Patrick J. McGovern a través de una subvención otorgada al co-investigador Simon Grandjean Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic Monitoring*)

Investigador Principal

Carlos Chaccour

Teléfono +34 666 293 112

Email cchaccour@unav.es

Este formulario de autorización cuenta con dos partes:

- Hoja de información (para compartir la información relevante al proyecto con usted)
- Certificado de Autorización (donde se le solicitará su firma y la de su padre, madre o representante legal, en caso de que acepte participar).

Le será proveída una copia del Certificado de Autorización.

**Parte I: Hoja de Información****Introducción**

Nos dirigimos a usted para informarle sobre un estudio de investigación en el que se le invita a participar. El estudio ha sido aprobado por el Comité de Ética de la Investigación de la Universidad de Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité independiente de ética del Centre Hospitalier de l'Université de Montreal (CHUM), en Canadá.

No es necesario que tome una decisión hoy. Puede tomarse el tiempo de hablar y discutir su participación con cualquier persona con la que se sienta cómodo haciéndolo.

Con este documento pretendemos que usted reciba la información adecuada para que pueda entender de qué se trata este estudio y decidir si quiere o no participar en el mismo. Es posible que haya palabras o información que no entienda. De ser así, siéntase libre de preguntar cualquier duda.

Generalidades del estudio

Los coronavirus son un grupo de virus que causan infecciones respiratorias generalmente leves. Sin embargo, un miembro de este grupo, el SARS-CoV-2, es el responsable de provocar la COVID-19, una enfermedad potencialmente peligrosa que desde finales del 2019 se ha extendido a lo largo de todo el mundo.

Uno de los elementos necesarios para contener el avance de la pandemia de COVID-19 es entender su escala real. Esto es particularmente importante ahora que los brotes regulares en zonas en las que simultáneamente ocurre transmisión a una menor escala se han convertido en una realidad. Uno de los mayores obstáculos de los sistemas sanitarios es la limitada capacidad de hacer pruebas diagnósticas, lo que se traduce en retrasos en la búsqueda de atención médica, así como en la recolección de la información necesaria para planear intervenciones que limiten la expansión de la enfermedad.

La gran mayoría de pacientes con COVID-19 presentan tos como un síntoma temprano de la enfermedad. Este estudio pretende evaluar la utilidad de una aplicación para el móvil, llamada HyfeApp, que registra y evalúa patrones de tos, como complemento a las estrategias de vigilancia epidemiológica existentes. Para esto, estimamos que será necesario grabar y analizar al menos 15,500 episodios individuales de tos.

Por eso esperamos que el mayor número posible de voluntarios instale la aplicación, la cual se ejecuta en segundo plano en el móvil. Aunque HyfeApp tiene acceso continuo al micrófono de su móvil, ha



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
sido diseñada para procesar únicamente sonidos compatibles con las características de la tos humana. Cuando uno de estos sonidos es detectado y grabado por la aplicación, un algoritmo de inteligencia artificial lo estudia y en caso de decidir qué se trata de un episodio de tos, se guarda junto a información sobre la ubicación geográfica y el momento en que ocurrió, que es proporcionada por el sistema GPS del móvil.

Aparte de la información suministrada por la aplicación, revisaremos los registros médicos de aquellas personas dispuestas a participar que acudan a consulta en el sistema nacional de salud, o la Clínica Universidad de Navarra. El objetivo de esto es recolectar información sobre la presencia de tos durante la exploración médica, o el diagnóstico de alguna enfermedad respiratoria en alguna de las visitas. Solo se consultará información relacionada con alguna de las siguientes condiciones:

- Tos no específica.
- Infecciones del tracto respiratorio superior.
- Faringitis.
- Asma.
- Bronquitis.
- Enfermedad Broncopulmonar Obstructiva Crónica (EBPOC).
- COVID-19
- Enfermedad por Reflujo Gastroesofágico (ERGE)
- Influenza
- Neumonía (por cualquier causa)
- Infección por virus sincitial respiratorio (VSR)
- Infecciones respiratorias inespecíficas.

Otros exámenes paraclínicos a ser recolectados incluyen:

- Microbiología
 - pruebas de COVID-19
 - PCR para influenza
 - Cultivo de esputo
- Hematología
 - Hematología completa
 - Prueba del dímero D.
- Bioquímica
 - Proteína C reactiva
 - Procalcitonina
 - CPK
 - LDH
 - Ferritina

Aparte de la información obtenida de la app y sus registros médicos, también le pediremos a un grupo reducido de participantes que formen parte de discusiones grupales focalizadas, para explorar los desafíos que representa el uso continuo de HyfeApp, y su participación en el estudio. En caso de que se le solicite participar, usted podrá aceptar o negarse.



Duración

Se recolectará información inicialmente por un período de 1 mes, consultándosele en ese momento su disposición a seguir participando por 3 y 6 meses. Usted podrá negarse a seguir participando en el estudio en cualquier momento.

Procedimientos del estudio

Usted no puede participar en el ensayo si usted:

- No puede o no quiere aceptar compartir su información codificada relacionada a sus registros de tos con bases de datos globales usadas para refinar los diagnósticos basados en perfiles acústicos.
- Si no posee un teléfono inteligente en el que se pueda ejecutar HyfeApp.
- Tiene menos de 13 años de edad.
- No es un estudiante/trabajador de la Universidad, o un paciente diagnosticado con una enfermedad causante de tos en la Clínica Universidad de Navarra.
- Si no reside en Navarra.

Si usted decide participar, un miembro de nuestro equipo lo ayudará a instalar la aplicación en su móvil. No serán necesarias nuevas visitas de parte del equipo de investigación, pero serán contactados una vez al mes para obtener comentarios sobre su experiencia usando la aplicación y ratificar su consentimiento y disposición a seguir participando en el estudio. También podrá ser contactado vía correo electrónico para recibir actualizaciones periódicas sobre el estado del proyecto y sus resultados preliminares.

La aplicación HyfeApp

HyfeApp es una aplicación móvil disponible para los sistemas operativos Android y iOS (Apple), desarrollada por un equipo multidisciplinario que incluye analistas de datos, desarrolladores de software y médicos especialistas en enfermedades infecciosas.

¿Qué cosas hace HyfeApp?

HyfeApp se ejecuta constantemente en el segundo plano de su móvil, sin interferir con el funcionamiento de otras aplicaciones, pero teniendo acceso a su micrófono y grabando recortes explosivos de sonido de menos de 0.5 segundos de duración. Ni las conversaciones, ni los sonidos de fondo son grabados. Estos recortes son enviados a un servidor, donde un algoritmo de inteligencia artificial identifica aquellos que presentan cambios súbitos y cortos en los decibeles, compatibles con episodios de tos. Posteriormente, otro algoritmo los procesa, evaluando otras características y determinando si efectivamente se trató de un episodio de tos. El servidor envía esta información de



vuelta al móvil, de forma que los archivos clasificados como tos se incorporan a los registros mostrados por la aplicación.

HyfeApp es una herramienta que le proporciona información sobre su estado de bienestar. Tal como herramientas similares que cuentan calorías, registran el número de pasos o ronquidos. La única diferencia es que HyfeApp cuenta episodios de tos.

12 **Beneficios y riesgos por su participación en estudio**

14 HyfeApp le permitirá llevar un registro del número de veces que tose al día, así como evidenciar
15 cambios con respecto a días anteriores. Sin embargo, no es una herramienta de diagnóstico o
16 tratamiento médico. Por lo tanto, ni provee información o consejos médicos, ni sustituye de ninguna
17 forma a los servicios sanitarios: HyfeApp no es un instrumento médico especializado. Si usted tiene
18 alguna duda sobre su estado de salud, debe consultarlas con un médico o en caso de emergencia,
19 llamar a los servicios respectivos inmediatamente .
20
21

24 Grabar sonidos desde un móvil inmediatamente genera dudas sobre la forma en que será manejada
25 la información, y garantizada la privacidad de los participantes. Como hemos explicado anteriormente,
26 HyfeApp no graba conversaciones ni sonidos de ambiente. Los segmentos de 0.5 segundos grabados
27 por la aplicación no permiten identificar a los participantes. Sin embargo, algunos de estos sonidos
28 pudiesen permitir identificar al participante si son interpretados en conjunto con otra metadata
29 registrada por la aplicación (como el número de teléfono, por ejemplo). Por esta razón, toda la
30 información transmitida por la aplicación estará encriptada y manejada según los protocolos de
31 seguridad estándar empleados en este tipo de estudios. De esta forma, únicamente los investigadores
32 podrán asociar los datos recolectados por la aplicación, a otros elementos que permitan identificar a
33 los participantes.
34
35

36 Usted no recibirá un pago por su participación.
37
38

41 **Participación Voluntaria**

42 Debe saber que su participación en este estudio es voluntaria y que puede decidir no participar o
43 cambiar su decisión y retirar la autorización en cualquier momento, sin que por ello se altere la
44 relación con su médico ni se produzca perjuicio alguno en su tratamiento.
45
46

48 **Pagos y Compensación Económica**

51 El promotor del estudio es el responsable de gestionar la financiación del mismo. Para la realización
52 del estudio, el promotor ha firmado un contrato con el centro donde se va a realizar y con el médico
53 del estudio.
54

55 Su participación en este estudio no le causará costes adicionales diferentes de los asociados a su
56 tratamiento habitual. La asistencia rutinaria deberá ser pagada por la seguridad social, por su seguro
57 médico o por usted mismo.
58

59 Ni usted ni sus padres/representantes recibirán un pago por su participación en este estudio.
60



Otra Información

Cualquier nueva información referente a la aplicación utilizada en el estudio y que pueda afectar su disposición para participar en el mismo, que se descubra durante su participación, le será comunicada lo antes posible.

Si usted decide retirar el consentimiento para participar en este estudio no se añadirán nuevos datos a la base de datos y puede exigir la destrucción de cualquier información identificable previamente retenida, para evitar la realización de nuevos análisis.

También debe saber que puede ser excluido del estudio si el promotor y/o los investigadores del mismo lo consideran oportuno, ya sea por motivos de seguridad, por cualquier acontecimiento adverso derivado de su participación, o porque consideren que no está cumpliendo con los procedimientos establecidos. En cualquiera de los casos, usted recibirá una explicación adecuada del motivo que ha ocasionado su retirada del estudio.

Confidencialidad

Toda la información recolectada en este estudio se mantendrá codificada, de forma que no pueda ser vinculada a sus datos personales. Solo el investigador principal y los co-investigadores sabrán su nombre y en cualquier documento o comunicación se usará un número de identificación personal asignado a cada participante. Las computadoras utilizadas para analizar los datos de este estudio tendrán contraseñas y solo investigadores autorizados podrán acceder a ellas.

La Universidad de Navarra, como responsable del tratamiento de datos, se compromete al cumplimiento de la Ley Orgánica del 3/2018, de 5 de diciembre y demás normativa de protección de datos en vigor. Por ello, es importante que conozca la siguiente información:

• Además de los derechos que ya conoce (acceso, modificación, oposición y cancelación de datos) ahora también puede limitar el tratamiento de datos que sean incorrectos, solicitar una copia o que se trasladen a un tercero (portabilidad) los datos que usted ha facilitado para el estudio. Para ejercer sus derechos, diríjase al Delegado de Protección de Datos de la institución en [protecciondedatosnav@unav.es]. Así mismo tiene derecho a dirigirse a la Agencia de Protección de Datos si no quedara satisfecho/a.

• Tanto el Centro como el Promotor son responsables respectivamente del tratamiento de sus datos y se comprometen a cumplir con la normativa de protección de datos en vigor. Los datos recogidos para el estudio estarán identificados mediante un código, de manera que no se incluya información que pueda identificarle, y sólo su médico del estudio/collaboradores podrá relacionar dichos datos con usted y con su historia clínica. Por lo tanto, su identidad no será revelada a ninguna otra persona salvo a las autoridades sanitarias, cuando así lo requieran o en casos de urgencia médica. Los Comités de Ética de la Investigación, los representantes de la Autoridad Sanitaria en materia de inspección y el personal autorizado por el Promotor, únicamente podrán acceder para comprobar los datos personales, los procedimientos del estudio clínico y el cumplimiento de las normas de buena práctica clínica (siempre manteniendo la confidencialidad de la información).



• El Investigador y el Promotor están obligados a conservar los datos recogidos para el estudio al menos hasta 25 años tras su finalización. Posteriormente, su información personal sólo se conservará por el centro para el cuidado de su salud y por el promotor para otros fines de investigación científica si usted hubiera otorgado su consentimiento para ello, y si así lo permite la ley y requisitos éticos aplicables.

• Si realizáramos transferencia de sus datos codificados fuera de la UE a las entidades de nuestro grupo, a prestadores de servicios o a investigadores científicos que colaboren con nosotros, los datos del participante quedarán protegidos con salvaguardas tales como contratos u otros mecanismos por las autoridades de protección de datos. Si el participante quiere saber más al respecto, puede contactar al Delegado de Protección de Datos del promotor [protecciondedatosnav@unav.es].

Compartiendo los Resultados

Usted tendrá acceso a todo el conocimiento generado por esta investigación en todo momento, solo debe preguntar al investigador principal. No compartiremos su nombre, estado de salud o dirección. Eventualmente, los resultados serán publicados, de forma tal que cualquier persona interesada en conocerlos, pueda acceder a ellos. Usted podrá solicitar información sobre el status y los resultados del estudio, preguntándole directamente al investigador principal.

¿Quién aprobó esta investigación?

El estudio ha sido aprobado por el Comité de Ética de la Investigación de la Universidad de Navarra, el comité de ética de la investigación con medicamentos de Navarra y el comité independiente de ética del Centre Hospitalier de l'Universite de Montreal (CHUM), en Canadá.

Derecho a negarse a participar o abandonar el estudio

- No tiene que participar en este estudio si no desea hacerlo.
- Tiene el derecho a NO firmar este formulario. Si no desea firmar este formulario, no podrá participar en este estudio de investigación. Esto se debe a que necesitamos su permiso por escrito antes de poder usar su información.
- Tiene el derecho a abandonar este estudio incluso después de haber aceptado participar. Si decide abandonar el estudio, no usaremos su información. En caso de decidir abandonar el estudio, por favor comuníquese con un miembro de nuestro personal. No tiene que explicar sus razones para abandonar el estudio.

A quién contactar

Si no está satisfecho con la forma en que se llevó a cabo este estudio, o tiene alguna duda, queja o pregunta sobre sus derechos como participante, por favor contacte a la oficina de atención al paciente de la Clínica Universidad de Navarra, por teléfono (+34 948 255 400) o correo electrónico ([attpatientun@unav.es](mailto:atpatientun@unav.es)), para hablar con alguien independiente del equipo investigador.



Si tiene alguna duda sobre este estudio o sus procedimientos, ahora o en el futuro, puede comunicarse con: Dr. Carlos Chaccour. Teléfono: 628 659 003. Quién es el investigador principal del estudio. Puede llamar de Lunes a Viernes entre las 8:00 y las 17:00 horas.

Parte II: Certificado de Autorización

Autorización del padre o representante legal

He leído o se me ha leído la información anterior. Se me permitió hacer preguntas al respecto y cualquier pregunta que haya hecho me fue contestada de forma satisfactoria.

Autorizo que mi hijo/hija o representado legal participe en este proyecto de investigación.

No autorizo que mi hijo/hija o representado legal participe en este proyecto de investigación y no he firmado la autorización presente a continuación.

Nombre del padre o representante legal:

Firma del padre o representante legal:

Fecha (dd/mm/aaaa)

Consentimiento del menor de edad

He leído o se me ha leído la información anterior. Se me permitió hacer preguntas al respecto y cualquier pregunta que haya hecho me fue contestada de forma satisfactoria.

Acepto participar en este proyecto de investigación.

No acepto participar en este proyecto de investigación y no he firmado la autorización presente a continuación.

En caso de que el menor acepte participar:

Nombre del menor de edad:

Firma del menor de edad

Fecha (dd/mm/aaaa):

En caso de no saber leer o escribir

Un testigo que sepa leer o escribir debe firmar (este individuo debería de ser posible, haber sido elegido por el participante, no su parente o representante, y no estar relacionado con el equipo de



investigación). Todo participante que no sepa leer o escribir debe presentar la huella digital de su pulgar.

Soy testigo de que este formulario fue leído de forma precisa al participante en potencia, y que dicho individuo tuvo la oportunidad para hacer preguntas. Confirmo que el individuo en cuestión ha autorizado su participación de forma voluntaria.

Nombre del testigo:

Firma del testigo:

Fecha (dd/mm/aaaa):

Huella digital del pulgar del participante:



Declaración del encargado de obtener la autorización

He leído de forma precisa la hoja de información al participante en potencia, y he hecho todo lo posible para asegurarme de que entendiera que se realizarán los siguientes procedimientos:

1. La aplicación HyfeApp deberá ser descargada en el móvil del participante.
2. La aplicación HyfeApp registrará y almacenará sonidos compatibles con la tos humana durante un período de un año, entre octubre de 2020 y septiembre de 2021.
3. En caso de acudir a una consulta en el sistema nacional de salud, la información médica del participante podrá ser accedida para buscar evidencia clínica de tos o alguna enfermedad respiratoria.

Confirmo que al participante se le ha dado la oportunidad de hacer preguntas sobre la investigación y que todas esas preguntas han sido contestadas de forma apropiada y de la mejor forma posible. Confirmo que el individuo no ha sido forzado a autorizar su participación, y que su consentimiento ha sido libre y voluntario.

Una copia de este certificado de autorización ha sido proporcionada al padre o representante legal del participante.

El padre o representante legal del participante ha firmado el consentimiento informado: Si _____
No _____

Nombre de la persona a cargo de obtener el consentimiento:



1
2
3 Firma de la persona a cargo de obtener el consentimiento:
4
5 Fecha (dd/mm/aaaa):
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3 English version
4
5
6

7 Participant ID:
8
9

10 **Information sheet and assent form for the participation of minors aged 13-18 years in the research**
11 **study titled:**
12

13 Version 3.0 January 6th, 2021
14
15

16 *Acoustic surveillance and digital cough monitoring at population level for early respiratory disease*
17 *outbreak detection, an exploratory observational study*
18
19
20

21 This assent form is meant for minors who are interested in taking part in the previously mentioned
22 observational study. Please read this form carefully with your parents or legal guardian and ask any
23 questions you might have.
24
25
26

27 **Promoter**
28
29

30 Clínica Universidad de Navarra/Universidad de Navarra, Avenida de Pío XII, 36
31 31008 Pamplona.
32
33

34 **Funder**
35
36

37 This study is funded by the Centre Hospitalier de l'Université de Montreal (CHUM) and the Patrick
38 J. McGovern Foundation through a grant awarded to Co-Investigator Simon Grandjean
39 Lapierre (*Early diagnosis of COVID-19 by utilizing Artificial Intelligence and Acoustic*
40 *Monitoring*)
41
42

43 **Main Researcher**
44
45

46 Carlos Chaccour
47 Teléfono +34 666 293 112
48 Email cchaccour@unav.es
49
50

51 This document consists of two parts:
52
53

- 54 ● Information sheet (meant to explain relevant information regarding the project).
55 ● Assent form (where we will require your signature, and that of your parent or legal guardian,
56 if you decide to take part in it).
57
58

59 You will be provided a copy of this document for your personal records.
60



Part I: Information sheet

Introduction

The objective of this document is to inform you about the characteristics of a research study you have been invited to participate in. The study has been approved by the Committee of Research Ethics of the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the independent ethics committee from the Centre Hospitalier de l'Université de Montreal (CHUM), in Canada.

This document aims to provide you with proper information, so you can understand this study and decide by yourself if you are willing to take part or not in it. Please read this information document carefully and we will answer any questions that might come up afterwards. You can also discuss this with people you trust before making a decision.

Objective of the research

Coronaviruses are a group of viruses that cause generally mild respiratory disease. However, a member of this group, the SARS-CoV-2, is responsible for causing COVID-19, a potentially dangerous disease that has spread across the globe since 2019.

One of the necessary interventions to contain the COVID-19 pandemic is understanding its real scale. This is particularly important now that new outbreaks are being regularly reported in areas with ongoing low-level transmission. A major limitation in this process is the limited diagnostic capabilities of many countries, which translates into delays in the search of medical attention and the collection of necessary epidemiological data.

Most patients with COVID-19 present cough as an early symptom of disease. This study aims to evaluate the usefulness of a mobile app called HyfeApp, which registers and studies cough patterns, as a complement to existing disease surveillance strategies. To do this, we will need to record and analyse about 15,500 individual episodes of cough. The town of Cizur Menor has been selected as the location of the initial studies of this new platform.

For this reason, we need as many people as possible installing the app, which runs in the background of your mobile. Although HyfeApp has continuous access to the mobile's mic, it has been designed to exclusively process sounds that match the characteristics of human cough. When one of these sounds is detected and recorded, an artificial intelligence algorithm studies it and where it determines it does sound like an episode of cough, the record is stored, along with geographical information and time, provided by the mobile's GPS.

Besides the information from the app, we will also review the medical records of those participants who present for a medical consultation in the national health system or the Clinica Universidad de Navarra. The objective of this is to collect information about the presence of cough, or any respiratory disease during one of those visits. Data from your medical chart will be obtained by the investigators from your local clinic or hospital. This includes without being limited to information related to any of the following conditions will be reviewed:

- Non-specific cough
- Non-specific upper respiratory tract infections
- Pharyngitis
- Asthma
- Bronchitis



- Chronic Obstructive Pulmonary Disease (COPD)
- COVID-19
- Gastro-esophageal reflux disease (GERD)
- Influenza
- Pneumonia (any cause)
- Respiratory Syncytial virus
- Non-specific respiratory tract infections

Additional laboratory test data to be captured from the selected visits includes:

- Microbiology
 - COVID-19 tests
 - Flu PCR
 - Sputum culture
- Hematology
 - Full blood count
 - D-dimer test
- Biochemistry
 - C-reactive protein
 - Procalcitonin
 - CPK
 - LDH
 - Ferritin

Besides the information from the app and medical charts, we will also solicit a restricted number of participants to participate in focus group discussions to explore the challenges related to using HyfeApp and participating in this study. If solicited, it will be your right to accept or refuse to participate in those focus groups.

Duration

Data will be initially collected for a one-month period. You will then be offered the opportunity to continue in the study for 3 and 6 months. You can refuse continuing in the study at any point.

Study Procedures

You will not be able to enroll in this study if you:

- Are incapable or unwilling to accept to share your codified cough data with multicenter databases aiming at refining acoustic-based diagnostics.
- Are under 13 years of age.
- Do not own a smartphone able to run HyfeApp.
- Are not a student/worker at the University of Navarra or a patient diagnosed with cough-related disease at the Clínica Universidad de Navarra.
- Are not a resident of Navarra

In case you decide to take part, a member of our team will help you install the app on your mobile. No further visits from the research team will be necessary. But you might be contacted once a month to collect feedback on your experience using the app, as well as to confirm your willingness to continue in the study. You might also receive periodic updates via email, to keep you informed on the status of the project and relevant preliminary results.

About HyfeApp



HyfeApp is a mobile app available for Android and IOS (Apple) operative systems, developed by a multidisciplinary team of data scientists, software developers and infectious disease physicians.

What does HyfeApp do?

HyfeApp runs in the background of your mobile, without interfering with any other running app, but having constant access to your mic and recording explosive sound snips of 0.5 seconds or less. No conversations, nor ambient sounds are recorded. These sound snips are sent to a server, where an artificial intelligence algorithm identifies those presenting sudden, shortchanges in decibel levels, compatible with cough episodes. Then, another algorithm processes them, evaluating its characteristics and determining if they were in fact, cough. The server then sends that data back to the mobile, so those files labeled as cough episodes are displayed by the app. HyfeApp is a wellness status tool. Just like similar apps that count calories, steps or snores. The only difference is that HyfeApp counts episodes of cough.

Benefits and risks of participating

HyfeApp will allow you to have a record of the number of times you cough every day, and of any changes compared to previous days. However, it is not a diagnostic or treatment tool. Therefore, it does not provide medical advice, nor replaces healthcare services. HyfeApp is not medical equipment. If you ever have doubts regarding your health condition or status, you should consult a doctor, or in case of emergency, communicate with proper emergency services.

We are aware that recording sounds from a mobile phone generates doubts regarding the handling of information and the participants' privacy. As explained before, HyfeApp does not record conversations or ambient sounds, and the 0.5 second sound snips are too short to identify participants. However, if linked to other metadata (such as telephone numbers), these sounds could allow identification. For this reason, all the information transmitted by the app is encrypted and handled following standard safety protocols. This way, we can make sure that only the researchers can access potentially identifiable data.

You will not be paid for your participation.

Voluntary participation

You must know that your participation in this study is voluntary and you can decide not to take part, or change your mind and resign your consent at any time in the future. This will not affect your relationship with your healthcare provider, nor harm your access to proper medical treatment in any way.

Economic Compensation

The study promoter is responsible for managing the funds. Before, doing a research study, the promoter must have signed a contract with the center where the study will take place, and the doctors who will conduct the study. Your participation in this study will not cost you any extra money beyond your standard medical procedures. Routine medical assistance will have to be paid by the social security network, your medical insurance, or yourself.



You will not receive any payment or monetary compensation for taking part in this study.

Other information

Any new information regarding the app to be used in this study and that could affect your disposition to take part in it, discovered after you have decided to participate, will be communicated to you as soon as possible.

If you wish to withdraw your consent to take part in the study, no further personal data will be added to the database. You can also demand the destruction of any previously retained identifiable information, to prevent new analysis from being carried on.

You must also know that you could be excluded from the study if the promoter and/or researchers consider it to be adequate, either for your own safety, to prevent any adverse consequence deriving from your participation, or because they consider you are not complying with the established procedures. In any case, you will always receive a proper explanation of what caused your withdrawal from the study.

Confidentiality

All the information collected in this study will be codified in such a way that they cannot be linked to your personal data. Only the main researcher and co-researchers will know your name, and an ID number will be used to refer to you in every document or communication. The computers used to store and analyse the data will be password-protected and only authorised researchers will have access to them.

The Clínica Universidad de Navarra, as the data controller, complies with the Organic Law 3/2018, of December 5, and other Spanish data protection regulations in force. Therefore, it is important that you know the following information:

• In addition to the rights that you already know (access, modification, refusal and cancellation of data), you can now also limit the processing of incorrect data, request a copy, or have the data that you provided be transferred to a third party (portability) for the study. To exercise your rights, contact the Institution's Data Protection Officer at [protecciondedatosnav@unav.es]. You also have the right to contact the Data Protection Agency if you are not satisfied.

• Both the Center and the Promoter are respectively responsible for the processing of your data and undertake to comply with the data protection regulations in force. The data collected for the study will be identified by a code, so that information that can identify you is not included, and only your study doctor / collaborators will be able to relate said data to you and to your medical history. Therefore, your identity will not be revealed to any other person except to the health authorities, when required, or in cases of medical emergency. The Research Ethics Committees, the representatives of the Health Authority in matters of inspection and the personnel authorized by the Sponsor, may only access to verify personal data, clinical study procedures and compliance with the rules of good clinical practice (always maintaining the confidentiality of the information).

• The Researcher and the Sponsor are obliged to keep the data collected for the study for at least 25 years after its completion. Subsequently, your personal information will only be kept by the center for



the care of your health and by the promoter for other scientific research purposes if you have given your consent to do so, and if this is allowed by the law and applicable ethical requirements.

- If we transfer your encrypted data outside the EU to our group entities, service providers or scientific researchers who collaborate with us, the participant's data will be protected with safeguards such as contracts or other mechanisms by the protection authorities of data. If the participant wants to know more about it, he or she can contact the promoter's Data Protection Officer [protecciondedatosnav@unav.es].

Sharing the results

At all time, you will have access to the knowledge we get from the research upon request to the principal investigator. We will not share your name, health status or where you live. After this, we will publish the results so that other interested people may learn from our research. You will be able to ask the status of this study and its findings by a direct request to the principal investigator.

Who approved this research?

The study has been approved by the Committee of Research Ethics of the Universidad de Navarra and the Committee of Medication Ethics of Navarra (Spain), as well as the independent ethics committee from the Centre Hospitalaire de l'Université de Montréal (CHUM), in Canada.

Right to refuse or withdraw

You don't have to take part in this research study if you do not wish so. You have the right not to sign this form. If you do not sign this form, you cannot take part in this research study. This is because we need your written permission to use your information. You have the right to leave the research study. If you would like to leave the research study, please tell a member of the study staff. You do not need to explain why you want to leave.

Who to contact?

If you are not satisfied with the way this study was conducted, or if you have any concerns, complaints or general questions about your rights as a participant, please contact the Patient Attention Office at the Clínica Universidad de Navarra by phone (+34 948 255 400) or email atpacientun@unav.es to talk with someone independent of the research team.

If you have any questions about this study or study procedures now or in the future, you can call Dr. Carlos Chaccour. Tel number 628 659 003 who is the Principal Investigator of the study. You can call Monday-Friday from 8.00 to 17.00 hrs.

Part II: Assent Form

Authorization from the parent or legal guardian

I have read, or have been read to the previous information. I was allowed to ask questions and I was provided with satisfactory answers to each one.

I authorize my child/minor under my care to take part in this research project.



1
2
3 I do not authorize my child/minor under my care to take part in this
4 research project and I have not signed the Assent Form presented below.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Name of parent or legal guardian:

Signature of parent or legal guardian:

Date (dd/mm/yyyy):

Consent from the minor

I have read or have been read to the previous information. I was allowed to ask questions and I was provided with satisfactory answers to each one.

I accept to take part in this research project.

I do not accept to take part in this research project and I have not signed the assent form presented below.

In case the minor accepts to participate:

Name of minor:

Signature of minor:

Date (dd/mm/yyyy):

If illiterate:

A literate witness must sign this form (when possible, this person should be chosen by the participant and not be related to the research team). Every illiterate participant must still present a fingerprint of his/her thumb.


I confirm this form was properly and accurately read to the potential participant and that said individual has voluntarily consented to participate in the study.

Name of witness:

Signature of witness:

Date (dd/mm/yyyy):

Participant's fingerprint (thumb):



Statement from the person responsible of getting written consent



I have, to the best of my ability, read this information sheet to the potential participant and made my best effort to make sure he/she understood that the following procedures will be performed:

1. HyfeApp will be downloaded to the participant's mobile phone.
2. HyfeApp will register and store sounds that match the characteristics of human cough for a one-year period, between October 2020 and September 2021.
3. If the participant seeks medical attention through the national health network, his/her medical records could be accessed by the researchers to look for evidence of cough or any respiratory disease.

I confirm the participant has been allowed to ask questions and that all his/her questions have been answered to the best of my ability. I confirm the participant has not been coerced to take part in this study and that his consent was free and voluntary.

A copy of this form will be provided to the parent or legal guardian for personal records.

Has the parent or legal guardian signed the assent form?: Yes No

Name of the person in charge of obtaining the participant's consent:

Signature of the person in charge of obtaining the participant's consent:

Date (dd/mm/yyyy):

**Cuestionario complementario de información médica****Versión 2.0 (6 de enero, 2021)****Información personal**

Nombre: _____

Primer Apellido: _____

Segundo Apellido: _____

Fecha de nacimiento: _____

DNI: _____

Sistema operativo del móvil:

- Apple
- Android

Ciudad o pueblo _____ Avenida/Calle _____

Número _____ Escalera (izquierda o derecha, solo para departamentos) _____

Piso _____ Puerta _____

¿Usualmente usted recibe atención médica a través de cuál de los siguientes proveedores de salud?

- Público (Seguridad Social/Osasunbidea)
- Privado (Clínica Universidad de Navarra)
- Ambos

¿Ha sufrido usted de alguna de las siguientes condiciones en el pasado, o sufre de alguna en la actualidad?

- Tos de causa no específica o desconocida
- Infecciones no especificadas de las vías respiratorias altas (Sinusitis, otitis, laringitis)
- Faringitis
- Asma
- Bronquitis
- Enfermedad broncopulmonar obstructiva crónica (EBPOC)
- COVID-19
- Enfermedad de Reflujo Gastroesofágico (ERGE)
- Influenza estacional



- 1 Neumonía (sin importar la causa)
- 2 Infección por virus sincitial respiratorio
- 3 Otras infecciones no especificadas del tracto respiratorio inferior
- 4 Fumador
- 5 Otra condición

12
13 En caso de haber seleccionado la
14 opción “Otra condición”, por favor
15 explique a continuación a que se
16 refiere:
17

18
19 _____
20 _____
21 _____
22



1
2
3
4
5 English version
6

7 Medical Information Questionnaire for participants recruited at the University of Navarra
8

9 Version 2.0 (January 6th, 2021)
10
11
12

13 The following information must be filled by participants who have consented to take part in the study
14
15
16
17

18 Participant information
19

20 Name: _____
21

22 First surname: _____
23

24 Second surname: _____
25

26 DOB: _____
27

28 DNI: _____
29

30 Participant's mobile operating system:
31

- 32 Apple
33 Android
34

35 Residence city _____ Street _____
36

37 Number _____ Stair (left or right, only for apartment buildings) _____
38

39 Floor _____ Door _____
40

41 Usually, you receive medical care from which of the following providers?
42

- 43 Public health network (Social Security/Osasunbidea)
44 Private (Clínica Universidad de Navarra)
45 Both
46

47 Please indicate if you have suffered from any of the following medical conditions
48
49
50
51
52
53
54
55
56
57
58
59
60



- 1 Non-specific cough
- 2 Non-specific upper respiratory tract infections
- 3 Acute pharyngitis
- 4 Asthma
- 5 Bronchitis
- 6 Chronic Obstructive Pulmonary Disease (COPD)
- 7 COVID-19
- 8 Gastroesophageal Reflux Disease (GERD)
- 9 Influenza
- 10 Pneumonia (any cause)
- 11 Respiratory Syncytial Virus Disease
- 12 Another non-specific lower respiratory tract infection
- 13 Smoker
- 14 Other condition (please specify): _____
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
		Digital Acoustic Surveillance for Respiratory Disease Outbreak Early Detection: An Exploratory Observational Study in Navarra, Spain

Administrative information

Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry..... p. 3
	2b	All items from the World Health Organization Trial Registration Data Set.....NA
Protocol version	3	Date and version identifier..... NA
Funding	4	Sources and types of financial, material, and other support..... P. 18
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors..... p. 0, 18
	5b	Name and contact information for the trial sponsor.....p.0
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities..... p. 18-19
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)..... NA

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention..... p.5-7
Objectives	7	Explanation for choice of comparators..... p.5-7
Trial design	8	Specific objectives or hypotheses..... p.8
		Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)..... p. 7

Methods: Participants, interventions, and outcomes

- Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained..... p.7
- Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)..... p.8
- Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered..... p.9-11
- 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)..... NA
- 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests).....p.9
- 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial.....NA
- Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended..... p-12-14.
- Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended..... p. 7-8, Figure 1.
- Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations.....p.12
- Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size.....p.7

Methods: Assignment of interventions (for controlled trials)

Allocation:

- Sequence generation 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions.....NA

Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned.....NA
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions.....NA
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and How..... NA
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial.....NA
Methods: Data collection, management, and analysis		
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol.....p.8,12-14.
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols.....p.9.
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.....p.13-14.
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.....p.12-14.
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses).....p.13.
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation).....NA

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed.....NA.
-----------------	-----	---

- | | | |
|----------|-----|--|
| | 21b | Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.....NA |
| Harms | 22 | Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct.....p.14 |
| Auditing | 23 | Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the Sponsor.....NA. |

Ethics and dissemination

- | | | |
|-------------------------------|-----|---|
| Research ethics approval | 24 | Plans for seeking research ethics committee/institutional review board (REC/IRB) approval.....p.14 |
| Protocol amendments | 25 | Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators).....p.14 |
| Consent or assent | 26a | Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32).....p.7-8 |
| | 26b | Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable.....NA |
| Confidentiality | 27 | How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial.....p.14 |
| Declaration of interests | 28 | Financial and other competing interests for principal investigators for the overall trial and each study site.....p.19 |
| Access to data | 29 | Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators..... Data share agreement included in the research agreement, but not in this submission. |
| Ancillary and post-trial care | 30 | Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation.....NA |
| Dissemination policy | 31a | Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions.....p.14-15 |
| | 31b | Authorship eligibility guidelines and any intended use of professional writers.....p.18 |
| | 31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code.....NA |

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates..... Yes
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable.....NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.